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Separation-based determinations of peptides hold the promise of measuring the 
concentrations of many peptides and their metabolites. However, typical chromatographic 
methods bear disadvantages in their selectivity and/or sensitivities. Thus, means for lowering 
detection limits are needed. The biuret reaction, the coordination of Cu(II) and peptides in basic 
solutions, provides a sensitive detection method based on the reversible Cu(III)/Cu(II) 
electrochemistry in peptide-bonded states. 
Thyrotropin-releasing hormone (TRH) is an important neuropeptide that undergoes the 
biuret reaction. The cationic form of TRH is not retained in a typical reversed-phase column. We 
have modified the common acidic mobile phase for peptide separation with a surfactant to retain 
the cationic TRH. A surfactant-preconditioned packed-bed capillary serves as the sample loop to 
preconcentrate TRH through sequential loading. The preconcentration has improved the 
detection limit for TRH 50-fold in the capillary HPLC-EC system.  
TRH lacks the N-terminal amine and C-terminal carboxylate that are usually required in 
the biuret reactions of Cu(II) and tripeptides. The unique structure of TRH affects the 
electrochemical behavior of the complex. We have utilized various electrochemical and 
spectroscopic techniques to determine the stoichiometry of the complex and to identify the 
binding sites in the peptide. Our data reveal that the interactions between Cu(II) and TRH are 
also possible under physiological pH.   
iii 
 
The unusual structure of TRH complicates the electrochemistry of Cu(II)-TRH complex. 
Multiple chemical reactions accompany the redox processes. We have investigated the kinetics 
of the coupling reactions using a rotating ring-disk electrode. The results suggest deprotonation 
of  the ligand and inter-molecular interactions between complexes.   
Using microelectrode voltammetry, we have discovered that the octarepeat peptide of the 
prion protein is involved in Cu(II)/Cu(I) electrochemistry at physiological pH. This observation 
is relevant to the copper toxicity: Cu(II) may be reduced in vivo to Cu(I), which reacts with 
hydrogen peroxide to produce damaging oxidative radicals. The octarepeat peptide stabilizes 
Cu(I) by altering its redox potentials. Thus, the prion protein may have a function of anti-copper-
toxicity. 
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 1. Introduction: Neuropeptides and Their Interactions with Cu(II) 
 
 
1 
 1.1. Neuropeptides and Biuret Method for Peptide Analysis 
The mammalian brain exerts its functions through neurons and glial cells that 
communicate through the release of chemicals, namely neurotransmitters, into the extracellular 
space. Over 100 neurotransmitters, some of which are peptides, have been identified [1]. It is of 
great importance and interest to monitor these chemical messengers to understand behavior, 
disease and mental illness and how such malfunctions might be corrected. 
Since neuropeptides always coexist with many other neurotransmitters, separation is 
usually required to perform sensible and reliable analysis of peptides. Reversed-phase High 
Performance Liquid chromatography (RP-HPLC) is a popular technique that bears a number of 
advantages. It is the ideal separation method for polar and non-volatile samples with a wide 
range of molecular weights and ionic properties. These features are characteristic of many 
biological molecules. Development of capillary HPLC has allowed the use of sample sizes down 
to sub-microliters and also led to lower mass detection limits [2,3]. Reversed-phase LC with 
0.1% TFA and an acetonitrile gradient has worked satisfactorily for the separation of peptides. 
Using these conditions, high resolution separations with 100-150 peaks per chromatogram can be 
achieved.   
Most neuropeptides exist in mammalian brains in the low µM range [4]. The extracellular 
concentrations are typically 1 – 100 pM. A useful detection method should be capable of 
detecting attomole levels in microliter samples. Commonly used detection techniques for LC 
include ultraviolet [5,6], fluorescence [7,8], mass spectrometry [9], immunoassay [10] and 
electrochemical detection [3,5,8]. UV absorbance detection lacks sensitivity towards small 
peptides (10-8 - 10-6 M detection limit [5,6]) because of poor selectivity. Considering the small 
light path length in capillary separation systems which additionally lowers the sensitivity, 
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 absorbance detection is not suitable for neuropeptide determinations. Table 1-1 compares the 
selectivities and sensitivities of the other methods. 
Table 1-1. Characteristics of commonly used detection method for peptides following HPLC separation. 
Detector Derivatization Detection Limit (M) Selectivity References 
Fluorescence Pre-column 10-11 - 10-9  Amine or Thiol [7,8] 
Mass Spec None 10-9 - 10-7 Universal [9] 
Immunoassay Off-line 10-13 - 10-10 Epitope [10] 
Electrochemistry None 10-12 - 10-9 Trp, Tyr, Cys [3,5,8] 
 
Table 1-1 implies disadvantages associated with the listed methods despite their high 
sensitivity. The specificity of immunoassay is low in the presence of cross-reactive species [11]. 
Necessary modifications, such as truncation and deamidation, may lead to peptide 
microheterogeneity and influence data interpretation [12]. Fluorescence detection depends on the 
derivatization of amine or thiol groups, thus the reaction is not specific for peptides. Multiple 
derivatization sometimes occurs on peptides bearing multiple amine groups and interferes with 
quantification. Electrospray mass spectrometry is well suited for coupling with microseparation 
techniques. Yet, since its sensitivity is closely related to the spray rate, the interface, the 
operation mode, the m/z ratio, and the solution matrix [13], this detection method is better for 
qualification purposes rather than quantification, unless coupled with clean-up/preconcentration 
procedures to improve ionization efficiency and sensitivity [2]. Direct electrochemical methods 
apparently have very limited application. 
Few methods among the above allow for both sensitive and selective peptide detection. 
Another detection scheme that is peptide-specific and characterized by low detection limits is 
electrochemical detection based on the biuret reaction.   
3 
 The biuret reaction refers to the coordination of Cu(II) ion with deprotonated amide 
nitrogens in alkaline solutions. The name “biuret” came from half a century ago. Cu(II) forms a 
complex with biuret, H2N-CO-NH-CO-NH2, in pH > 13 aqueous alkali [14]. In the 1980s, the 
analytical value of the biuret reaction were recognized [15,16] -- in the form of a biuret complex, 
Cu(II) is reversibly oxidized to Cu(III) at practical potentials, typically 0.5 – 0.8 V vs Ag/AgCl 
at pH 10. With excess Cu(II), the oxidation is quantitative with respect to peptide concentrations. 
Based on the reversibility of the redox reaction, dual electrode detectors in flow systems provide 
additional selectivity toward peptides and high signal-to-noise ratios on the downstream 
electrode. The biuret detection scheme is compatible with the most common mobile phase for 
peptide analysis, namely 0.1% TFA in water-acetonitrile gradient [15]. The reaction takes place 
in a few seconds for most peptides investigated [15], meaning post-column derivatization is 
possible. With post-column derivatization, the detection does not interfere with the separation 
mechanism. Detection limits for non-electroactive peptides at the cathode range from 20 - 200 
fmol (100 µL of a 0.2 - 1 nM solution) and 6 - 40 fmol (100 µL of a 60 - 400 pM solution) at the 
anode for electroactive peptides [17]. 
Biuret detection of peptides for HPLC thus provides good selectivity for peptides as well 
as high sensitivity. However, neuropeptides are diverse in structures and ionic properties. It is 
necessary to explore the applicability of biuret detection method on some special yet important 
neuropeptides. To allow low sample volume analysis necessary for some biological samples, a 
capillary HPLC system is ultimately preferred. This brings in new requirements for the 
separation, post-column reaction and detection. 
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 1.2. Biuret complexes: structure and electrochemical implications 
In the HPLC system, a post-column derivativatization reaction needs to be quantitative 
and fast enough to take place within a limited flow path (so as to avoid band broadening). It is 
necessary to study the coordination and electrochemical kinetics of biuret complexes for a better 
understanding of the applicability of the detection method. 
1.2.1. Regular peptides 
Metal-, especially Cu(II)-, complexes of peptides have been studied to a great extent. 
Initial interest arose from the surprising ability of Cu(II) to promote amide deprotonation. Amide 
deprotonation typically occurs at pH 15, while the biuret reaction takes place around pH 10 [18]. 
Figure 1-1 shows a typical structure of a copper complex of a tripeptide. 
 
Figure 1-1. Typical structure of Cu(II)-tripeptide complex. 
Side chains R1 – R3 do not participate in the coordination. 
 
Typical peptides, which we define as having an N-terminal amine group, C-terminal 
carboxyl group, and non-coordinating sidechains, bind Cu(II) initially from the primary amine 
nitrogen. As shown in Figure 1-2, the binding at first involves the amide carbonyl oxygen and 
facilitates the deprotonation of the nearby amide nitrogen which replaces the oxygen to bind 
Cu(II). For N-blocked peptides, the coordination is slower and may require other conditions such 
as higher pH or higher temperature [19]. In this case, the C-terminal carboxylate group has been 
suggested to initiate the coordination [20]. 
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Figure 1-2. Typical procedure of Cu(II)-tripeptide coordination. 
Side chains R1 – R3 do not participate in the coordination. 
 
Cu(II)-peptide complexes usually are square planer structures with four equatorial ligands, 
resulting from Jahn-Teller effects. The equatorial donors determine most of the characteristics of 
the complex, including optical and electrochemical properties. Depending on the actual 
conditional pKa values of each amide nitrogen and the environmental pH, components of NNOO 
(one amine nitrogen, one deprotonated peptide amido nitrogen, and two carbonyl oxygens or one 
carbonyl and one carboxylate oxygen), NNNO (one amine nitrogen, two deprotonated peptide 
amido nitrogen, and one carbonyl/carboxyle oxygen) and NNNN (one amine nitrogen and three 
deprotonated peptide amido nitrogens) equatorial binding modes can co-exist.  
The strong nitrogen ligating brings the Cu(III)/Cu(II) redox potential down to practical 
values. At pH 9.8, a Cu(II)-peptide complex with the NNNN binding mode is oxidized at 0.4 – 
0.6 V and a complex of NNNO binding mode at 0.7 – 0.9 V, all vs. Ag/AgCl [18,19]. For regular 
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 peptides, the coordination is fast enough to be used in a post-column detection method in an 
HPLC system  [15]. 
The Cu(III)/Cu(II) redox couple when bonded to peptides is not a simple case. The 
rotating ring-disk electrode (RRDE) has proven powerful in elucidating the electrochemical 
kinetics of Cu(II) complexes of model peptides [21]. Homogeneous chemical reactions exist both 
prior to and after the oxidation. The chemical reactions following oxidation are related to peptide 
backbone and have been observed in the redox processes of Cu(II)-polyglycine complexes 
[21,22].  
By comparing the diffusion layer thickness at an electrode surface in a channel-type flow 
cell and at a rotating disc electrode (RDE), RDE experiments can be used to investigate flow cell 
behavior. With regular peptides there are no following chemical reactions in the typical 
microbore or capillary HPLC systems [15,23,24].  
However, many neuropeptides are not “regular”. Electron-donating side chains are 
common as many peptides contain residues such as His, Cys, Glu, etc. Some peptides lack a free 
amine or carboxylate at the termini. The diversity of neupeptides adds a challenge and 
excitement to the biuret reaction-based electrochemical detection method. 
1.2.2. Peptides containing His residues 
Some sidechains are electron donating. These include the imidazole in His, the 
carboxylate in Asp and Glu, and the nitrogens in Arg in their deprotonated state. These side 
chains, especially the former two, may participate in coordination.  
The imidazole moiety of the His side chain offers a basic binding site. The pKa  ranges 
from 6.0 to 7.1 [25,26]. Cu(II) may promote the deprotonation through coordination. For 
example, a 120-mer poly-histidine binds Cu(II) with three imidazole and one peptide bond amido 
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 nitrogen at pH 5 [27]. Coordination of Cu(II) with His-containing peptides can occur at a lower 
pH than required by ordinary biuret reaction (typically pH 9.8). Many proteins interact with 
Cu(II) under physiological conditions through their His residues, such as Cu,Zn-superoxide 
dismutase [28,29], bovine serum albumin [30], and the pathogenic proteins prion [31] and 
amyloid-β peptide [32].  
 
 
Sp3 Sp2
Sp2
Sp3
 
Figure 1-3. The tautomeric forms of the  imidazole nitrogens. 
 
The nitrogen that is closer to the alkyl link to the peptide backbone is often annotated as 
π-N, 3-N or pyridine-N. The one that is farther away is annotated as τ-N, 1-N, or pyrrole-N. 
They undergo rapid tautomeric exchange when not bound (Figure 1-3). When interacting with 
suitable metal ions, it is the 3-N that binds metal to form a six-membered ring along with other 
peptide backbone donors [26] (Figure 1-4). Being a stronger donor than carboxylate or carbonyl 
oxygen, the imidazole nitrogen can replace the oxygens to form a more stable Cu(II) complex. 
This is not always the case. Besides taking an equatorial binding position, the imidazole of a 
histidine residue may also occupy an axial position of the same [27,33], or even another Cu(II) 
ion to form a dimer [34].  
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Figure 1-4. The imidazole 3-N participates in binding Cu(II). 
 
Though not as competitive, the pyrrole nitrogen (1-N) of peptide Gly-His has been 
suggested to deprotonate at higher pH and bind equi-molar Cu2+, Ni2+ or Pd2+ [35]. The 
imidazole moiety thus acts as a bridge and promoted bi-nuclear complex formation. The 
argument is based on a deprotonation at pH higher than 9.6 accompanied by a blue shift in the d-
d transition of the Cu2+ and Pd2+ complexes. The deprotonation has been reported to be 
concentration dependent, which is favored by the bi-nuclear complex formation. With tripeptide 
Gly-Gly-His as the ligand, similar deprotonation of the pyrrole-nitrogen has been suggested. 
There was no shift in the d-d transition band, which was explained through the hypothesis that 
the deprotonated nitrogen does not bind any metal ions [36]. 
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 1.3. The octarepeat peptide of the prion protein and its interaction with Cu(II) 
1.3.1. PrP and prion diseases. 
Prion proteins (PrP) in the past decade have caused worldwide interest. Its misfolding and 
aggregation in neurons affect the nearby neurons quickly, resulting in lethal and transmissible 
prion diseases [37]. Prion diseases affect various mammals and exist as mad cow disease in cattle, 
scrapie in sheep and goats, chronic wasting disease in deer and elk, and kuru and Creutzfeldt-
Jakob disease (CJD) in human [38,39]. These transmissible diseases can be spread by means of 
infected food, transplant tissues or blood products, all imposing a potential menace to human life. 
There is thus a need to understand the normal functions and misfolding mechanism of the prion 
proteins. 
The existence of prion protein in brain was not noticed until the breakouts of prion 
diseases. No notable functions of the protein have been discovered other than causing the 
neurodegenerative diseases. PrP-knockout mice do not show considerable difference when 
compared to wild type mice in their behavior or brain tissue [40]. This suggested that the normal 
function of PrP is subtle. Moreover, the knockouts stay free of infection for twice as long as the 
wild type controls after being inoculated with the pathogenic prions, PrPSC [41,42]. These results 
have convincingly pointed out that it is, critically, the conversion of normal PrP to PrPSC, not the 
PrPSC itself, that leads to prion diseases.  
The pathological behavior of PrP has analogs in other neurodegenerative diseases, such 
as the aggregation of β-amyloid protein in Alzheimer’s disease [43,44] and of α-synuclein in 
Parkinson’s disease [45-47]. In both diseases, metal ions have been found to play important roles 
[48-51]. In 1995, Hornshaw’s study of Cu(II)’s binding with synthetic PrP repeat units [52] 
started the exploration of the interaction of PrP with metal ions, especially Cu(II). 
10 
 1.3.2. PrP as a metal binding protein. 
Prion protein is a glycoprotein of about 230 residues, 
variation depending on the actual species, with residues 1-22 
attached to the cell membrane. The C-terminus of the protein 
adopts a highly conserved alpha-helical structure, while the N-
terminus is more flexible.  
 
Figure 1-5. Metal binding regions in full length prion protein. 
 
Several regions of the prion molecule have shown 
substantial affinity for transition metal ions. These regions 
include segments 92-96, 106-126 and the N-terminal octarepeats 
59-91 [53-56]. Their metal-binding ability is attributed to the histidine residues [57]. Figure 1-5 
shows a normal prion protein molecule and the N-terminal histidines where metal ions are often 
found to bind [55]. The octarepeat region features multiple tandem copies of the eight-residue 
sequence PHGGGWGQ. Most interestingly, this domain is highly conserved across species [58], 
suggesting roles in possible PrP function.  
The metal-binding property of the octarepeat region gave rise to the hypothesis that prion 
protein may have metal-related functions. Suggestions surrounding this hypothesis, including 
transporting extracellular copper ion into the cell interior and maintaining cellular copper balance 
[59-62] and protecting neurons in excessive oxidative stress [63-65], have been proposed.  
1.3.3. Cu(II)-octarepeat coordination. 
Many techniques have served in the studies of Cu(II)-octarepeat coordination. These 
include electron paramagnetic resonance spectroscopy (EPR) [66], nuclear magnetic resonance 
11 
 spectroscopy [67], x-ray crystallography [62], x-ray absorption spectroscopy [68], circular 
dichroism (CD) [54,66], potentiometry and spectroscopy [69] and mass spectrometry [57,70]. 
Cu(II) is unique among all the transition metal ions that have been reported to bind PrP or 
its fragments: it displays quenching effect in Trp fluorescence spectroscopy while other metal 
ions do not [54], and the interactions between Cu(II) and a couple of metal-binding fragments of 
PrP are much stronger than those of Ni(II), Zn(II) and Mn(II), etc. [61]. A full length PrP picks 
up at most six Cu(II) ions. The main Cu(II) binding domain is the less folded N-terminal part, 
especially the octarepeats. Much evidence exists to show that each repeat unit binds one Cu(II) at 
physiological pH [66,70,71]. But at lower pH, one Cu(II) may need two repeat units to complete 
complexation [70]. In a single octarepeat, the five residue fragment Ac-HGGGW-NH2 acts as the 
fundamental binding unit [66]. A resolved crystal structure is shown in Figure 1-6. The crystal 
structure suggests indirect communication between the metal center and the tryptophan residue. 
Other authors argue that Trp does not exert any weak interaction with the metal center, and the 
apical oxygen donor is more likely an oxygen from either the amide carbonyl in front of His 
residue or the one of the third Gly [72]. The argument comes from both spectroscopic and 
electrochemical observations: the Cu(II) complex of single octarepeat at around pH 7 displays 
biuret-like absorption at 614 nm; it blue-shifts as pH increases to 10; at around neutral pH the 
complex displays a reduction signal at – 0.299 V (NHE); at pH 10, it shifts to – 0.308 V (NHE). 
These data can be explained when an axial water ligand is replaced by carbonyl oxygen, which is 
a rather stronger donor.  
Cu(II) binding motifs within the octarepeat domain have not been isolated. It has been 
suggested that the cooperative effects among octarepeat units [69,73] lead to stronger and more 
structured interaction than single octarepeat. 
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Figure 1-6. Crystal structure of Cu(II)-Ac-HGGGW-NH2 illustrating Cu(II) binding mode  
with the octarepeat unit peptide. 
Adopted from ref. [58]. 
 
With normal functions of the prion protein being unclear, more and more people have 
come to believe the protein works closely with metal ions. More interest focuses on copper. The 
notion comes not only from the comprehensive roles of copper in mammalian body, but also has 
to do with the highly conserved octarepeat region in mammal species [58]. 
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 1.4. Goals 
Peptides may react with metal ions. Study of the metal complexes will help to understand 
the roles, functions, and mechanism, etc., of important bioactive peptides or proteins, and 
pathways of important physiological processes. 
A number of techniques can be used to measure the spectroscopic, electrochemical, 
and/or magnetic properties of the metal complex of interest. These properties are often reflective 
of the electron configuration of the metal center, the donors, and the structure of the ligands. 
There have been documented correlations between metal-peptide complex structures and their 
signals of UV-Vis [74], nuclear magnetic resonance [75,76], electron spin resonance [77], 
voltammetry [17,18], and circular dichroism [78], etc. Since the properties of the complex 
depend greatly on the donors for a given metal ion, the fragment of a protein that interacts with 
the metal is often studied before the full length protein. Examples include the amyloid-β peptide 
1- 40 in the amyloid-β protein [79], the octarepeats 59 - 91 of the prion protein [66], and the His-
containig sequences in Cu, Zn-superoxide dismutatse [80]. 
In the following chapters, I will demonstrate the utilization of electrochemical methods, 
mainly rotating ring-disk electrode and microelectrode voltammetry and chronoamperometry, 
with help of various spectroscopic tools in solving a series of question regarding biuret 
complexes of a couple of bioactive peptides. Solutions to these questions help to extend the 
application of biuret detection scheme of neuropeptides to wider ranges of peptides, to elucidate 
the coordination nature of non-ordinary peptides, and to explore the Cu(II)-related functions of 
the prion protein octarepeat unit peptide. 
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 2. Online Preconcentration of Thyrotropin-Releasing Hormone (TRH)  
By SDS-Modified Reversed Phase Column for Microbore and Capillary  
High Performance Liquid Chromatography (HPLC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(This chapter contains materials from publication R. Meng, W. Xia, M. Sandberg, R. 
Stephens, S.G. Weber, J. Chromatogr. A 1071 (2005) 179. 
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 2.1. Abstract 
Thyrotropin-releasing hormone (TRH, pGlu-His-Pro-amide) is an important tripeptide 
existing in biological systems at low concentrations. It is a fairly hydrophilic peptide, cationic in 
acidic solutions. Preconcentration online before reversed phase chromatography separation can 
enhance concentration detection limits of hydrophobic, but not hydrophilic species. The 
Hydrophilic TRH can be preconcentrated using a reversed phase precolumn charged with sodium 
dodecyl sulfate (SDS). The separation also uses SDS. The preconcentration is effective for a 
microbore system, achieving detection limit of 250 pM for a sample size of 500 µl with 
electrochemical detection of the biuret complex formed post column. Preconcentration using an 
online precolumn is also effective in packed capillary HPLC with a detection limit of 3 nM in 24 
µl. 
22 
 2.2. Introduction 
Thyrotropin-releasing hormone (TRH) is an important neuropeptide originally discovered 
in the hypothalamus as a releasing factor for pituitary hormones such as Thyrotropin and 
prolactin [1,2]. From a therapeutic perspective, administration of TRH and some of its stable 
analogs, appear to have neuroprotective and anti-convulsive effects [3-8]. It is also present in 
other brain areas with proposed additional, although not yet fully elucidated, functions [9-11]. 
Radioimmunoassay (RIA) has been used for TRH assays in serum and various tissues 
from rat [12-16]. Though powerful, RIA suffers from the drawbacks that it is too selective to be 
useful for determining all the members in a family of related peptides, but may not be selective 
enough to determine a single peptide accurately. In fact, analogs of TRH that displayed similar 
immunoactivity as TRH have been found in various rat tissues [17-21]. Therefore, a “separate-
and-detect” approach is preferred. High-performance liquid chromatography (HPLC) with UV-
Vis detection only works at low sensitivity [22-25]. While fluorescence detection following 
HPLC or CZE separations is a powerful technique for the determination of amino acids and 
peptides, it typically requires a primary amine or thiol group in the targeted molecule to be 
derivatized. Neither of these two functional groups exists in TRH. Mass spectrometry (MS) 
coupled to chromatography has been used qualitatively in characterizing this peptide [20] and to 
determine the sequence of some of its analogs that may not be distinguishable in RIA [21,26,27]. 
There are very few works on quantification of TRH by MS and these are not routine methods. 
Reports were found on field-desorption ionization following LC [28] and on fast atom 
bombardment ionization following GC by looking at the fragments [29]. A simpler detection 
method with high sensitivity and selectivity is still desirable. 
23 
 Selective chromatographic detection of peptides has been established based on the 
reversible electrochemistry of the Cu(II)/Cu(III) couple in polydentate peptide complexes [30-
33]. The detection relies on the coordination reaction of peptides and Cu(II), also called the 
biuret reaction [34,35]. TRH forms electroactive complex with Cu(II) thus is proposed to be 
detectable with the above method. In rat brain, TRH concentration ranges from roughly 2 nM 
(cerebellum) to 350 nM (hypothalamus) [11]. The targeted sample for dialysate analysis – 
extracellular fluid, is expected to contain lower concentrations of TRH. The low endogenous 
levels in biological samples have been a challenge for the detection of bioactive peptides. One 
method to improve sensitivity is to preconcentrate the analytes. Moreover, on-line 
preconcentration is preferred over off-line for higher efficiency. 
Works on online preconcentration methods for liquid separations are limited, especially 
for capillary LC. For hydrophobic analytes (e.g. hydrophobic peptides), reversed phase 
precolumns as injection loops trap and preconcentrate the analytes [36,37]. A simpler alternative 
is to inject a large volume of sample in a lower strength solvent, and elute the retained analytes 
with the higher strength mobile phase [38-40]. This method evidently will not apply to 
hydrophilic molecules. TRH is a hydrophilic cation in weak acidic solution, while the general 
mobile phases for peptide separation have acidic pH due to trifluoroacetic acid (TFA). This 
makes preconcentration on the reversed-phase column head not very promising. For charged 
analytes, a few works about strong ion exchange precolumns have been reported. In an analysis 
of trypsin digested BSA, strong cationic peptide fragments which featured Arg or Lys as 
terminal residues were trapped in a 250 µm i.d. strong ion exchange precolumn and eluted by a 
neutral buffer prior to a microbore HPLC system [41]. In the present work, we describe an online 
preconcentration method to enrich TRH through sorption in the presence of a surfactant. Ionic 
24 
 interactions have been widely used in liquid chromatography to achieve better separation on 
reversed phase columns [42,43]. To our best knowledge, no works have been reported on 
surfactant-assisted online preconcentration of cationic peptides. 
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 2.3. Experimental 
2.3.1. Microbore HPLC 
Reagents and sources were as follows: Sodium carbonate, sodium bicarbonate, cupric 
sulfate pentahydrate, disodium tartrate dihydrate, and sodium dodecyl sulfate (SDS) were from 
Sigma (St. Louis, MO, USA) and used without further purification. TFA was from Avocado 
(Heysham, Lancs, UK). TRH was from Sigma and stored at - 20°C. Doubly deionized water 
used in all solutions was obtained through a Milli-Q system (Millipore, Bedford, MA, USA). All 
other common reagents were of AR grade or better and purchased from commercial sources. 
The chromatographic apparatus included a LC-10AD Shimadzu pump (Kyoto, Japan) 
delivering mobile phase (0.1% TFA, 2% 1-propanol, 20% acetonitrile and 3.0 mM SDS in water), 
a Rheodyne injector, and a Jupiter 150 × 1.0 mm C18 reversed phase column from Phenomenex 
(Torrance, CA, USA). The postcolumn biruet reagent (0.50 mM CuSO4, 3.0 mM sodium tartrate, 
and 1 M carbonate, pH 9.8) was delivered by a 100 DM syringe pump from ISCO (Lincoln, NE, 
USA). The typical flow rates were 50 µl/min in the column and 20 µl/min for the biuret reagent. 
All necessary fittings and tubings are from Upchurch (Oak harbor, Washington, USA). A mixing 
tee and teflon tubing with 100 µm i.d. and 12.5 µl volume were used as the postcolumn reactor. 
Both the column and the reactor were put in a temperature controller (model LC-23A, BAS, W. 
Lafayette, IN, USA) which was maintained at 50 °C.  
A 4.0×2.0 mm C18 guard column from Phenomenex was used as the preconcentration 
column (also called precolumn or preconcentration loop in this work). It was connected to the 
injector by a 16 cm 62 µm i.d. PEEK (polyetheretherketone) tube (about 0.5 µl). Before each 
loading, the precolumn was preconditioned with 1250 µl of 0.1 % TFA and 3.0 mM SDS 
solution. Then about 500 µl of analyte solution were loaded into the precolumn. For brain slice 
26 
 experiment 470 µl was loaded. There was a 2 minute or longer delay time before the injector was 
switched to injection position.  
The electrochemical detector was a BAS LC-4C thin layer flow cell, with a dual glassy 
carbon electrode (3.0 mm diameter) and a 13 µm thick teflon spacer (both from BAS). Detection 
potential was + 0.9 V at the upstream electrode, + 0.1 V at the downstream electrode vs. 
Ag/AgCl reference electrode (3 M NaCl, BAS). Data were collected and processed with 
EZChrom software (Sci. Software, San Ramon, CA, USA). 
2.3.2. Capillary HPLC 
Reagents and sources were as follows: TFA and 1-propanol were from Sigma; disodium 
tartrate dihydrate and sodium hydroxide were from Baker (Phillipsburgh, NJ, USA); copper 
sulfate pentahydrate was from Fisher (Pittsburgh, PA, USA); acetonitrile (ACN), sodium 
carbonate, and sodium bicarbonate were from EM Science (Gibbstown, NJ, USA); TRH was 
from Bachem (King of Prussia, PA, USA); SDS was from Fluka (Switzerland). The copper 
sulfate pentahydrate and disodium tartrate dihydrate were recrystallized once from water. All 
other reagents were used without further purification, but purities were taken into account in 
preparation. De-ionized water from a Millipore A10 Synthesis system was used for all solutions. 
All mobile phases and biuret reagent solutions were filtered through 0.45 mm nylon membranes 
(Osmonics, Minnetonka, MN, USA) before use. 
The chromatographic instrumentation included a Waters 600 E quaternary pump for 
mobile phase (0.1% TFA, 3% 1-propanol, 20% acetonitrile, and 2.2 mM SDS), a split tee for low 
flow rates, a VICI injector (Valco Instrument Company, Houston, TX, USA), and a home-
packed capillary column. Injections were made through 100 µm silica capillary with an 
Upchurch inline filter (part # M-520) to one of the injector ports. A Harvard Model 11 syringe 
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 pump (Harvard Apparatus, Inc. Holliston, MA, USA) was used to pump the biuret reagent (2.5 
mM CuSO4, 12.0 mM sodium tartrate, and 0.6 M carbonate, pH 9.83). Typical flow rates were 
800 nl/min for the HPLC and 250 nl/min for the biuret. The two streams were mixed for post-
column reaction in a home-made device [44]. At the end of the reactor, the copper(II)-peptide 
complexes were detected at + 0.80 V versus Ag/AgCl (3 M NaCl) with a 10 µm carbon fiber 
electrode 1.0 mm in length. The potential was controlled with a BAS Epsilon potentiostat. 
Capillary columns were slurry packed with the technique described previously [45]. 
Typically 100 µm silica capillaries were slurry packed with 2.0 µm prototype bridged hybrid C18 
(Waters, Milford, MA, USA) reversed-phase particles. The packed length was typically 6 to 8 
cm. The preconcentration loop was packed in a 7.0 cm long 75 µm i.d. silica capillary with 5 µm 
C18 packing material. The packed length was 2 mm. Before each loading it was preconditioned 
with a solution containing 0.1% TFA and 3.0 mM SDS. Reactors were constructed with 50 µm 
silica capillaries and 18 µm tungsten wires, according to previously published procedures [44]. 
The mixing length was 6 or 6.6 cm, stated in figure captions. 
All necessary fittings and tubings are from Upchurch. All syringes used are from 
Hamilton (Reno, NV, USA). 
2.3.3. Brain tissue samples 
The tissue samples were supplied by Prof. Mats Sandberg. The detailed preparation 
procedures have been previously described [43,46,47]. Briefly, rat hippocampus is homogenized 
and extracted with 90% (v/v) methanol. Lyophilized extracts are stored frozen until use. Before 
injection, samples were reconstituted in 500 µl water, sonicated 6 min, centrifuged for 10 min 
(Jouan, Winchester VA, 12,000 rpm), and filtered (0.2 µm). Typically, somewhat less than 500 
µl were recovered for injection.  
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 2.4. Results and discussion 
In the dual electrode detection mode, the downstream (cathode) electrode typically has a 
better baseline and signal to noise ratio than the upstream (anode) electrode. We will focus our 
discussion on the downstream electrode signals in microbore HPLC. 
As the post-column reaction is essential in the detection scheme, the mixer had to be 
optimized for complete reaction yet minimal band broadening. Preferably, the radial diffusion in 
the tubing needs to be predominant over axial diffusion and convection. We will call this regime 
of convective dispersion the Taylor regime [44,48]. It allows for good mixing when two flow 
streams come into one open tube without excessive band spreading. For microbore HPLC, a 
combine-and-split reactor achieved good mixing of eluents and biuret reagent. Figure 2-1 shows 
a sketch of this reactor. It operates in the Taylor regime under the employed flow rate of 70 
µl/min. Because of the three crosses employed, the reactor provides additional mixing over that 
in a single open tube with the same volume. The total reaction volume was 12.5 µl. This reactor 
was used throughout the microbore HPLC work. In the capillary HPLC experiments, staying in 
the Taylor regime, efficient mixing took place in a 120 nl capillary (50 µm i.d., 6.0 cm). 
 
 
 
                         
 
Mixing crosses Mixing tee 
From column 
 
Biuret solution 
 
Figure 2-1. Sketch of the combine-split reactor for microbore HPLC. 
The tubings connecting the crosses were 65 µm i.d., 40 cm long each. Crosses and the Tee have 0.05 cm through 
holes. Dimensions of the detection cell are in the experimental section. 
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 TRH is not retained in a typical TFA/ACN mobile phase (data not shown). This is due to 
the low molecular weight and high polarity of TRH. A hydrophobic anionic additive, 
heptafluorobutyric acid (HFBA), is able to shift the retention of TRH to longer times. 
Unfortunately, it was found that the added HFBA deactivated the electrode very quickly, making 
the detection irreproducible.  
Alternatively, 2 - 3 mM SDS retained TRH as an additive in the mobile phase. 
Acetonitrile had to be included in the mobile phase to achieve a practical retention time. Figure 
2-2 shows the signal and retention time of TRH standard at various fractions of ACN in the SDS-
containing mobile phase. In a 10% ACN mobile phase, TRH was not eluted within 40 minutes. 
Higher ACN level of 20% brought the TRH k’ to a reasonable value of 2 - 3. In capillary HPLC, 
this percentage of ACN gives a similar k’ value. 
 
 
Figure 2-2. Optimizing acetonitrile content in the SDS-containing mobile phase. 
Mobile phase contained 0.1% TFA, 2% 1-propanol, 3.0 mM SDS, and stated amount of ACN. TRH concentration: 
500 nM. Sample loop: 20 µl. ♦: Peak area; ?: Retention time. 
 
Under the above conditions, TRH displayed a linear response in the range of 100 to 500 
nM. The regression of peak area in nC vs TRH mass in pmol gave an intercept much smaller 
than its uncertainty. Regression with the calibration curve forced through zero yields y = 0.22x 
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 (R2 = 0.9845). The detection limit (3σ) is 4.8 nM. (S/N value for 100 nM injection was about 55, 
for 500 nM injection was about 400). 
In an effort to push the concentration detection limit to a lower level, we attempted to use 
the column head to preconcentrate TRH by analogy to reversed phase LC. However, because the 
large volume of low strength solvent (usually water) disturbed the equilibrium of SDS between 
the mobile and stationary phases, a long equilibration time, at least several hours, was found 
necessary to get reproducible separation.  
A postulated solution to this problem is to put a small C18 precolumn in the injection loop, 
which is preconditioned with SDS-containing aqueous solution. The SDS generates a negatively 
charged layer on the stationary phase by hydrophobic interaction. When the sample prepared in 
aqueous solution is loaded into the preconditioned precolumn, molecules partition between the 
“mobile phase” water and the SDS-modified stationary phase. During this procedure the anionic 
and neutral hydrophilic and weakly hydrophobic species go through the precolumn to waste, 
while the cations and hydrophobic species stay in the precolumn. When the loop is switched into 
the separation system, the mobile phase desorbs the TRH (and some SDS). One of the 
advantages of this strategy is that it removes the interfering species such as salts which 
commonly exist in biologic samples. 
It is interesting to find that the solvent composition of sample has a great effect on the 
preconcentration. Shown in Figure 2-3, TRH in water gave a much narrower peak than in 0.1 % 
TFA/3 mM SDS (the precondition solution). This implies that biological samples such as 
microdialysates could be directly introduced to the precolumn. 
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Figure 2-3. Comparison of preconcentrated TRH signals in SDS-containing solution and water. 
TRH concentration: 500 nM. Loaded volume: 500 µl. 
 
As a demonstration of the preconcentration approach, 500 µl of TRH standard solutions 
from 5 nM to 100 nM were loaded each time and detected. In Figure 2-4 the chromatograms 
show that both the retention time and peak width of TRH are consistent. Similar to the case 
without preconcentration, the intercept from regression (nC vs pmol) was also smaller than the 
associated standard error. Regression anew gave a calibration curve of y = 143.1x (R2 = 0.9490).  
 
 
Figure 2-4. Signals of preconcentrated TRH at different concentrations in microbore HPLC. 
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 The detection limits (3σ in each case) from chromatograms of 5 nM, 10 nM and 20 nM 
injections were 142 pM, 340 pM and 250 pM (S/N values are 105, 90 and 250 respectively). We 
conclude that 250 pM is the detection limit of this technique for TRH. 
The low detection limit obtained from this detection approach made analysis in biological 
samples promising. Homogenized rat brain tissue was then introduced into the setup. In Figure 2-
5, a clear peak is observed at the same retention time that TRH is eluted. It corresponds to 0.3 
pmol TRH per mg of hippocampus tissue. This value was within the concentration range from 
the literature [11,49,50]. The chromatogram is fairly clean because the preconcentration step 
removed many interfering species. 
 
 
Figure 2-5. TRH determination in a homogenized rat brain tissue sample by microbore HPLC. 
Sample was centrifuged, filtered and then diluted to 470 µl for loading and injection.  
The standard was 100 nM TRH. 
 
It could be concluded that the above preconcentration method was successful in terms of 
detection limit and compatibility with biological samples. Sensitivity was enough for 
physiological analysis, and selectivity was assured by the use of precolumn and dual electrode 
cell. However, there is a very serious drawback, which is the large sample size required for the 
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 determination. The loaded volume in the brain tissue analysis was 470 µl. This is not practical 
for many samples. In this perspective, the system volume had to be decreased to accommodate 
much smaller sample sizes. Accordingly, the preconcentration strategy had to be carried out in a 
capillary format. The chemistry behind it should work regardless of the size of the column. 
In a capillary chromatography systems there are two potential sources of extracolumn 
band spreading: precolumns and post column reactors. A locally developed post column reactor 
[44] has been demonstrated to meet the requirement of low sample volume and virtually no band 
broadening post column.  
As for the precolumn, there are no commercial guard columns to use as the precolumn to 
match the much smaller size of the separation column. In preparing precolumns with capillaries, 
not surprisingly, the system brought up some engineering issues. The most important concern 
was the void volume of the tubing that connects the precolumn to the injector relative to the 
volume of the precolumn. For uniform sample loading, the void volume should be negligible 
compared to that of the precolumn. However, it is extremely hard to achieve because the packed 
precolumn will already be very small. At the same time, the port-to-port distance of the injector 
determines the minimum length that can be used. If the capillary loop/precolumn is too short, the 
strain will lead to breakage. Larger i.d. capillaries, though providing lower back pressure and 
therefore allowing for easy manual injection, are easily broken at the frit. In order to reduce the 
unpacked void volume, shorter, smaller i.d. capillaries are preferred.  
Loop/precolumns that failed (broke at the frit) were (o.d./i.d., µm) 360/250, 330/180, and 
a system that was 360/40 in series with a < 1cm packed 360/250 and another 360/40. In the latter 
system, a single high pressure connector (LC Packings TF-250) covered the precolumn and 
overlapped with the 360/40 on both sides. On the other hand, loop/precolumns with thicker walls, 
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 360/75, were successful. For 75 µm i.d. silica capillary, a 7 cm total length preconcentration loop 
did not break on being connected to the injector. Only a 2 mm length at the end of this capillary 
was packed. The back pressure was low enough to be permit injection with a 50 µl Hamilton 
gastight syringe. 
To test if such a packed preconcentration loop works, TRH standard solutions of the 
same concentration were loaded into the loop at different loading volumes. Loaded volumes 
were corrected for the volume of the tubing from injection port to injector and the dead volume 
of an inline filter (1.5 µl total). After each loading, the loaded loop was switched into the system 
for analysis. The signals from Cu(II)-TRH were proportional to the loaded volume as expected, 
with a rather good correlation coefficient (see Figure 2-6). The bands were tailing to some extent, 
but the tailing did not get worse as loaded volume increased. This implied that the band shape 
was not affected by overloading of the precolumn, but by other parameters, most likely the 
construction of the precolumn.  
 
 
Figure 2-6. Responses of 500 nM TRH standard of different loaded volumes.  
Sample undergoes preconcentration in capillary HPLC. 
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 Figure 2-7 gives a comparison of the TRH signal before and after the preconcentration 
column was introduced. The 5 µM and 100 nM TRH standards gave similar signal to noise ratio 
(approximately 100 in both cases). Figure 2-7b signal corresponds to a detection limit of 3 nM. It 
can be concluded that after preconcentration the concentration sensitivity of the current detector 
to TRH could be increased up to 50 fold.  
Injection to injection repeatability is function of the amount injected for the microbore 
experiments. Coefficients of variation range from 3% for 5 nM (500 µl) injected to 21% for 100 
nM (500 µl) injected. For the capillary system, the coefficient of variation is about 20% for 
volumes of 8.5 and 13.5 µl (500 nM). 
 
 
T
should n
into the 
back pre 
Figure 2-7. TRH signals before and after preconcentration in capillary HPLC. 
The postcolumn mixing length was 6.0 cm in Figure 2-7a and 6.6 cm in Figure 2-7b.  
Other conditions are listed in experimental section. 
he precolumn can be improved by optimizing its construction. The packed length 
ot be too short, in that sufficient partition process was required to stack TRH molecules 
precolumn. On the other hand, the packed length could not be too long, otherwise the 
ssure introduced in loading the precolumn would be hard to handle. Large i.d. tubings 
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 can be used for larger packed volumes, if ways can be found to prevent the thinner-wall 
capillaries from snapping. To limit void volume is also very important. Currently, the volume 
ratio of the precolumn and the separation column is much smaller than that in the microbore 
HPLC. This is mostly due to the engineering restrictions associated with compromising between 
better mechanical strength as well as smaller void volume and bigger precolumn capacity. 
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 2.5. Conclusions 
 
SDS-modified precolumn as a preconcentration sample loop is successful. The same 
chemistry worked on both microbore and capillary HPLC systems. Introducing of 
preconcentration column improved the detection limit of TRH 30 – 50 fold in both systems.
 Analysis of biological samples, especially microdialysates, is ultimate in the study of 
neuropeptides. The capillary HPLC system has to be improved for this purpose. Two feasible 
ways are improvement of the precolumn construction and improvement of the electrochemical 
detector. 
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 3. Binding of Copper Ion to Thyrotropin-Releasing Hormone (TRH) and Its Analogs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(This chapter contains materials from publication R. Meng, J. Becker, F.-T. Lin, S. 
Saxena, S.G. Weber, Inorg. Chim. Acta 358 (2005) 2933.) 
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 3.1. Abstract 
Spectroscopy (UV-Vis, 1H-NMR, ESR) and electrochemistry revealed details of the 
structure of the Cu(II)-TRH (pyroglutamyl-histidyl-prolyl amide) complex. The 1H-NMR 
spectrum of TRH has been assigned. NMR spectra of TRH in presence of Cu(II) showed that 
Cu(II) initially binds TRH through the imidazole. TRH analogs, pGlu-His-Pro-OH, pGlu-(1-
Me)His-Pro-amide, pGlu-His-(3,4-dehydro)Pro-amide, pGlu-His-OH, pGlu-Glu-Pro-amide, and 
pGlu-Phe-Pro-amide provided comparison data. The stoichiometry of the major Cu(II)-TRH 
complex at pH 7.45 and greater is 1:1. The conditional formation constant (in pH 9.84 borate 
with 12.0 mM tartrate) for the formation of the complex is above 105 M-1. The coordination starts 
from the 1-N of the histidyl imidazole, and then proceeds along the backbone involving the 
deprotonated pGlu-His amide and the lactam nitrogen of the pGlu residue. The fourth equatorial 
donor is an oxygen donor from water. Hydroxide begins to replace the water before the pH 
reaches 11. Minority species with stoichiometry of Cu-(TRH)x (x = 2 – 4) probably exist at pH 
lower than 8.0. In non-buffered aqueous solutions, TRH acts as a monodentate ligand and forms 
a Cu(II)-(TRH)4 complex through imidazole nitrogens. All the His-containing analogs behave 
like TRH in terms of the above properties. 
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 3.2. Introduction 
The neuropeptide Thyrotropin-releasing hormone improves functional recovery after 
neurologic dysfunctions, such as brain trauma and epilepsy [1-3]. Produced in the hypothalamus, 
TRH has been found to exist in significant quantities in other brain regions in rats [4,5], which 
implies other bioactivities. The effects of regulating body temperature [6] and stimulating 
hepatic blood flow [7] have been reported recently. 
TRH exerts its effects through interactions with a membrane-bound receptor which has 
been found to be a member of the G-protein coupled receptor family [8]. Perlman et al. modeled 
TRH binding to its receptor. They claim that the carbonyl and NH of the pyroglutamyl moiety, 
the imidazole and the C-terminal amide are all involved in the interaction with receptor [9-11]. 
At the same time, these sites are potential electron donors for metal ions in that C=O, -NH-, and 
imidazole nitrogen atoms are known to be electron-rich. Ogawa et al. found that synaptic 
membranes carrying TRH receptors lose their function after pretreatment with metal ions in the 
absence of TRH, indicating irreversible changes [12]. Moreover, of the divalent ions they studied, 
Ni(II) was found to decrease TRH-receptor binding, while Cu(II) and Zn(II) were found to 
increase the binding at physiological serum concentrations (20 µM). The authors suggested that 
metal ions are important modulators of TRH activity.  
A few studies have been carried out on the coordination of TRH and analogs with 
biologically active metal ions, e.g. Cu(II) and Ni(II), using techniques including potentiometric 
titration and spectroscopic methods such as UV-Vis, CD and ESR [13,14]. In the case of 
coordination with Cu(II) at pH 9.5 - 10, there was a major disagreement on the number of 
coordinated nitrogens (2 nitrogens in ref. [13], 3 nitrogens in ref. [14]). While both works 
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 reported 1:1 stoichiometry of the complex, in ref. 14 the authors also claimed a major 1:2 metal-
ligand binding stoichiometry when ligand was in 5-fold excess. 
TRH-metal binding is important in another context. The sensitive and selective HPLC-
based method for peptides is well established, based on the reversible electrochemistry of the 
Cu(III)/Cu(II) couple in polydentate peptide complexes, or biuret complexes [15,16]. The 
concentration of the neuropeptide TRH can be determined by the above mentioned means [17]. 
In both cases, the interaction of TRH with its receptor and the determination of TRH 
concentration, it is important to understand the metal complex structure. In this aspect, the role of 
pH should draw significant attention. 
We also briefly studied the Cu(II) complexes of five TRH analogs in order to relate the 
nature of the coordination to the functional groups in the peptide side chain. These analogs are 
(abbreviations listed in parentheses): 
pGlu-His-OH       (pEH) 
pGlu-His-Pro-OH       (TRH-OH),  
pGlu-(1-Me-His)-Pro-amide      (MeHis2-TRH), 
pGlu-His-(3,4-dehydro-Pro)-amide    (deHPro3-TRH),  
pGlu-Glu-Pro-amide       (Glu2-TRH), and  
pGlu-Phe-Pro-amide       (Phe2-TRH).  
The data support the view that the most prevalent complex in neutral and basic solutions 
has 1:1 stoichiometry. The four equatorial donor atoms are the imidazole 1-N, and the amide 
nitrogens resulting from the deprotonation of the amide bonds between pGlu and His and the 
lactam of pGlu as well as a water oxygen. 
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 3.3. Experimental 
3.3.1. Chemicals 
TRH and all its analogs studied (all from Bachem, USA) were used without further 
purification, but purities were taken into account in preparation of solutions. All solutions were 
made in purified water using a Milli-Q A10 Synthesis water purification system (Millipore, USA) 
except for those used in NMR experiments in which D2O (Cambridge Isotope Lab, USA) was 
used. The carbonate buffer is a mixture of equi-molar sodium carbonate and bicarbonate (both 
from EM science, USA), each at half of the concentration specified, i.e., given concentrations are 
for total carbonate. Borate buffers were all prepared with Na2B4O7⋅10H2O (Sigma, USA) in 0.25 
M KNO3 (J.T. Baker, USA). The borate concentration was 0.050 M except for the pH effect 
experiments, in which case the concentration was 0.10 M. The pH values were adjusted with 
0.60 M boric acid or 4 M NaOH (both from EM science, USA), and measured with an Accumet® 
pHmeter (Fisher Sci., USA), standardized before each use. In ESR experiments, pH values were 
measured with pH test strips (Fisher Sci., USA) of the pH 5.5 and pH 9.0 solutions. These two 
pH values thus have one fewer significant figure. Na2HPO4 (0.126 M) - citric acid (0.037M) was 
used as a weakly acidic buffer. Copper-peptide solutions were prepared by adding the desired 
amount of stock solutions to buffer in the order of peptide then copper sulfate. Molar ratios were 
1:1 (Cu(II):peptide) unless otherwise specified. 
3.3.2. Instruments and procedures 
Room temperature was 20 ± 2°C during all experiments. 
UV-Vis spectroscopic instruments consisted of an HP 8453 spectrophotometer with HP 
8453E operating software. Spectra of copper–peptide complexes in 1 cm quartz cuvettes were 
measured over 400 – 1000 nm with a 0.5 s integration time, using deionized water as a solvent 
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 blank in all cases. The wavelengths of maximum absorption (λmax) were identified by taking the 
first derivative with PeakFit (Version 4 for Win32 by Jandel Software, USA). The complex 
called “Cu(H2O)62+” was CuSO4 in aqueous solution;  the Cu(OH)42- complex was prepared by 
adding dropwise 4 M NaOH to CuSO4 aqueous solution until the light blue Cu(OH)2 precipitate 
cleared up and a deep blue solution was obtained;  the Cu(II)-tartrate complex was a mixture of 
1.0 mM CuSO4 and 6.0 mM sodium tartrate in buffer;  and the Cu(II)-peptide complexes were 
mixtures of 1.0 mM corresponding peptide and 1.0 mM CuSO4 in buffer. 
TRH spectra of 1H-1H 2-D and 1H-13C 2-D NMR were recorded on an AVANCE 500 
NMR spectrometer from Bruker (Billerica, MA, USA). TRH spectra of 1H, 13C, DEPT 
(Distortionless Enhancement by Polarization Transfer) NMR and 1H spectra of Cu(II) titration 
experiments were carried out on an AVANCE 300 NMR spectrometer from Bruker. The 
temperature was controlled at 0 °C. In copper titration experiments, the concentration of TRH 
was 4.0 mM in 0.20 M carbonate prepared in D2O, with different concentrations of CuSO4.  
Electron spin resonance spectroscopy experiments were done with a Bruker Elexsys-
E580 FT/CW spectrometer equipped with a Bruker ER 4118X-MS3 split ring resonator. 
Continuous wave ESR spectra were recorded with a quality factor Q of about 1600, a field-
sweep of 600 Gauss, microwave power of 6.3 mW and modulation amplitude of 5 – 7 Gauss. All 
Cu(II)-TRH sample solutions were in 20%/80% glycerol/water (the glycerol was added as a 
cryoprotectant). The pH of each solution was adjusted with 2 M NaOH aqueous solution. All 
ESR experiments were carried out in the X-band (9.75 GHz) at a controlled temperature of 80 K. 
Electrochemical instruments consisted of a DT-29 glassy carbon/glassy carbon ring-disk 
electrode, an ASR-2 analytical rotator, an RDE-3 potentiostat (all from Pine Instrument Co., 
Grove City, PA, USA), and a WaveTek 852 filter (WaveTek, San Diego, CA, USA) set for low 
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 pass with 5 Hz cutoff frequency. A DT2802 chromatography board (Data Translation, Inc., USA) 
digitized the filtered analog signal to a personal computer. RRDE data were collected using 
EzChrom chromatography software (Scientific Software, Inc., San Raman, CA, USA). A 
platinum grid counter electrode and a BAS Ag/AgCl reference electrode (3 M NaCl) completed 
the electrochemical cell.  
Complex concentrations as a function of total metal and ligand concentrations were 
calculated using Mathcad 2001 professional (Mathsoft, USA). Molecular simulation was carried 
out with the software CAChe (Fujitsu, Ltd., Japan) version 6.1.1. Structures were first checked 
for correct valences and hybridizations, then optimized using Allinger’s standard MM3 force 
field model [18,19]. The following factors were taken into account when optimizing: bond 
stretch, bond angle, dihedral angle, improper torsion, van der Waals interaction, electrostatics 
interaction, hydrogen bond, torsion stretch, and bend-bend interactions. 
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 3.4. Results and discussion 
In basic Cu(II) solutions, for example pH 9.83 carbonate with tartrate in excess of Cu(II) 
ion, addition of TRH generates a bluish purple color with maximum absorption wavelength (λmax) 
about 590 nm (Table 3-1). This wavelength is substantially lower than that of CuSO4 aqueous 
solution (Cu(H2O)62+) or Cu(II)-tartrate complex, which are at 810 nm and 725 nm, respectively. 
Among the peptides studied, the characteristic bands are at similar wavelengths, except for Phe2-
TRH and Glu2-TRH. The half wave potential is also a robust indicator for the formation of the 
biuret complex.  
Table 3-1. Summary of spectroscopic and electrochemical properties of Cu(II) complexes of TRH and 
analogs. 
λmax (nm) εapp a (cm-1 M-1) E1/2 (mV) Ligands 
Carbonate Borate Carbonate Borate Carbonate Borate 
H2O b 810 17 n/t 
OH- b 637 n/t n/t 
Tartrate 729 701 51 36 N/A N/A 
pGlu-His 595 585 64 65.7 n/t 780 
TRH 595 588 58.7 59.6 780 785 
TRH-OH 596 588 55.1 65.9 778 n/t 
MeHis2-TRH 590 587 58.9 66.8 802 n/t 
deHPro3-TRH 590 588 55.5 61.4 787 n/t 
Glu2-TRH 730 ppt 54.4 N/A N/A n/t 
Phe2-TRH 730 ppt 51.6 N/A N/A n/t 
a Obtained by dividing the absorbance at λmax by Cu(II) concentration. 
b Not in buffer. 
N/A: no detectable signal available. n/t : not tested. ppt: precipitation. 
 
By coordination with peptides, the redox couple Cu(III)/Cu(II) has its oxidation potential 
significantly lowered to typically 0.5 – 0.8 V. Based on the distinguishable behavior of the two 
non-histidyl TRH analogs, we can conclude that for these N- and C-termini blocked peptides, 
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 His is necessary for the formation of  electrochemically active biuret complexes with Cu(II) ion. 
DeHPro3-TRH, TRH-OH and pGlu-His all behave like TRH, suggesting that the N-terminal Pro-
NH2 does not play an important role in the binding. 
3.4.1. The binding stoichiometry 
Tripeptides typically bind Cu(II) ion with 1:1 stoichiometry [20,21]. The tertiary histidyl-
prolinyl amide is, however, a weak donor [22,23], thus TRH may act as a dipeptide. The 
molecular binding stoichiometry was determined using “the method of continuous variation”, or 
Job’s plot (Figure 3-1). The total concentrations of Cu(II) and TRH were held constant, while the 
relative ratios varied for each sample, from 0:1 (all TRH) to 1:0 (all Cu(II)). For pH higher than 
8.0, a six-fold excess of tartrate over Cu(II) was included at the same concentration in each 
sample to prevent excess Cu(II) ion from precipitating. Cu(II) not bound to peptide absorbs light, 
so measured absorbances need to be corrected to give a measure of the concentrations of Cu(II)-
peptide complex. Assuming that the molar absorptivity of unbound Cu(II) is constant, we have 
CCu(total) = CCu-TRH + CCu-other. At a certain wavelength: 
)(
/
)( otherCuTRHCuTRHCuotherCutotalCu
TRHCuTRHCuotherCuotherCutotal
CC
CClA
−−−−
−−−−
−⋅+⋅=
⋅+⋅=
εεε
εε
 
The first term on the right side is just the absorbance of a sample with no peptide 
(“blank”). Thus, by subtracting a blank absorbance from the observed absorbance, a quantity 
)( )( otherCutotalCutotalnet CAA −⋅−= ε  is produced that is directly proportional to CCu-TRH. Anet 
values are then plotted against Cu(II) fraction in the total. The left half of each plot represents 
excess TRH, and the right half of the plot represents excess Cu(II). The extrapolations of both 
sides intersect at a Cu(II):peptide ratio indicating the complex stoichiometry. 
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Figure 3-1. Job’s plots of Cu(II)-TRH (1:1) complex at different pH. 
Absorbances are normalized to 2.0 mM total concentration. A: Recorded in borate buffers containing 12.0 mM 
KNaTar. B: in borate-H3BO3 buffers, except for ∗ standing for non-buffered aqueous solutions. 
 
The Job’s plots revealed 1:1 stoichiometry from pH 8.15 to 11.90, as shown in Fig 1A. 
The λmax and absorbance at this wavelength are also very similar from pH 8.15 to pH 9.91. 
Figure 3-1B shows Job’s plots at lower pH values. A 1:4 stoichiometry predominates in non-
buffered aqueous system (pH ranged between 5.2 – 5.7). The λmax was 592 nm. No other reports 
about this stoichiometry have been found in the literature. At both pH 7.45 and 7.10 the apex is 
not well-defined. Also, in both cases the apparent binding stoichiometry involves non-integral 
53 
 TRH per Cu(II) ion: 1.5 (3:2) at pH 7.10 and 1.1 (11:9) at pH 7.45. The deduction from these 
results at pH lower than 8 is that: 1) another component co-exists with the 1:1 complex;  2) 
binding is probably incomplete. The second component is a multi-peptide binding mode. A Cu-
(TRH)2 complex has been reported to account for ~70% of all Cu(II) between pH 7.5 and 10.0 
when ligand was at 5-fold excess [14]. Our spectroscopic data can not determine the actual order 
of TRH in the multi-peptide binding mode. It could be 1:2, 1:3 or 1:4. Also, according to Figure 
3-1B, at pH 7.45 the fraction of the second component is not as much as in the reference cited. It 
decreases with increasing pH, from a substantial fraction of the entire complex at pH 7.10, to a 
negligible amount at pH 8.15. At pH 7.45 it only represents a small fraction. Considering the pH 
dependence of the total apparent stoichiometry, deprotonation is involved in the formation of the 
1:1 complex. 
It draws interest that the binding of Cu(II) to TRH through amide groups can occur at 
physiological pH. Metal ions affect TRH-receptor interaction and TRH bioactivity. These 
observations were related to the tertiary conformation of TRH upon chelation [12,24]. The biuret 
complex of Cu(II) and TRH should play a significant role if the observed 1:1 binding exists at 
the much lower concentrations of both TRH and Cu(II) in biological environment. The molar 
absorptivity of the d-d transition investigated is too low at physiological concentrations to make 
measurements. Knowledge of the formation constant is required to predict the extent of 
coordination. In principle, our Job’s plots contain information on the formation constants. 
However, in practice this method only works at a concentration range where binding is not 
complete. At the sub-milimolar concentrations adopted in typical visible spectroscopic 
measurements, the binding of Cu(II) and TRH is completed to a great extent, shown by the well-
defined sharp apexes in Job’s plots of pH 8.15 to pH 11.90. The observed formation constant 
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 Kobs (
])[]([])[]([
][
complexTRHcomplexCu
complexK
totaltotal
obs −⋅−= ) is estimated as no lower than 10
5 M-1, 
but more accurate determination is not possible from these data. 
Yamada et al. [14] reported the formation constants of 1:1 and 1:2 Cu(II)-TRH 
complexes which agreed with a few other values [25,26]. The average values are logβ1=-7.70 for 
MH-2L and logβ2 = -5.42 for MH-2L2 (M – metal, L – ligand, H-2 – two deprotonations). These 
numbers were obtained from pH titration experiment at tens of mM concentrations and 5-fold 
excess ligand. Under these conditions, the authors saw more than 70% of Cu(II) as a 1:2 complex 
in the pH range of 7.5 - 10. Based on their formation constant values, the corresponding 
conditional formation constants at pH 7.45 were calculated (by multiplying each β by [H+]-2) and 
used in a calculation of Job’s experiment. In the calculation it was assumed that the 1:1 and 1:2 
stoichiometry are the only forms of coordination. The result showed the fraction of 1:2 
stoichiometry decreased dramatically with decreasing concentration and peptide:Cu(II) ratio.  
At the concentrations used in our Job’s experiments, MH-2L (1:1) predominates. When 
TRH is in excess, no more than 10% of Cu(II) exists as MH-2L2. When Cu(II) is in excess, there 
is virtually no MH-2L2. Physiologically, Cu(II) is in large excess of TRH. TRH exists in rat brain 
at nM concentrations [4], while Cu(II) has been determined with values ranging from 
approximately 40 to 150 µM [27,28]. At this excess, TRH forms predominantly a 1:1 complex 
with Cu(II). As calculated for 5 nM TRH and 50 µM Cu(II), 99.9% of TRH is bound with Cu(II) 
at 1:1 ratio. In the brain, the Cu(II) activity is certainly less than 50 µM, however, the complex is 
still predominantly 1:1. For example, with 5 nM TRH and 50 nM Cu(II), about 40% of TRH is 
bound with Cu(II) at 1:1 ratio. The concentration of the 1:2 species is 10-6 times lower.  
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 For the computations above we used literature values for the binding constants. Our 
estimate of the formation constant of the 1:1 species is somewhat lower than the one used. The 
discrepancy is likely due to the difference in Cu(II) activity coefficients. Our measurements 
involved coordinating ions, nitrate and tartrate, and as such, the conditional constants derived 
from the data have little meaning in general. Nonetheless, the 1:1 coordination of Cu(II) and 
TRH can not be ruled out as an important  process occurring biologically. 
3.4.2. The equatorial donors 
Billo [29] developed a correlation between the absorption maxima for Cu(II) complexes 
and the number and type of equatorial donors. With slight modification of the factors, the 
correlation worked well on multidentate ligands such as peptides [30]. According to this equation, 
the experimental λmax data (pH 9.84) from the four histidyl-containing peptide complexes in 
Table 3-1 are consistent with the NNNO binding mode, in which each Cu(II) ion has three 
nitrogen atoms and one oxygen atom as equatorial donors. In fact, from pH 7.45 to 9.91, Cu(II)-
TRH coordination fell in the NNNO binding region. 
Electron Spin Resonance (ESR) can also give evidence of the number of nitrogen donors 
in Cu(II) complexes, often of peptides and proteins [31-33]. For Cu(II), the four features due to 
the parallel component of the hyperfine interaction (A||, with the nucleus of spin 3/2) can often be 
resolved near the g|| (the parallel component of the axially symmetric g-tensor) region of the 
spectrum. The magnitude of A|| and g|| are dependent on, among many factors, the ligand 
environment of Cu(II). Peisach and Blumberg [33] showed the dependence of A|| and g|| values 
and total charge of Cu(II) complexes on the ligand environment. Generally, as the number of 
nitrogen donors increases, all the four peaks shift to higher field. The A|| value also increases, 
from 120 G to 220 G when all four oxygen donors are replaced with nitrogen. At the same time, 
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 g|| value decreases from 2.4 to 2.1. Millhauser et al. reported the binding modes of a Cu(II) 
complex and the prion protein octarepeats change from OOOO to NNNN in the pH range of 4.10 
to 11.6 [32]. Their correlation between A|| and g|| values and the binding mode agreed with 
Peisach’s.  
 
Figure 3-2. The g|| region of Cu(II) ESR spectra in presence of TRH. 
Cu(II) and TRH were 1.0 mM each. The A|| value at pH 10.76 was obtained by simulating the spectrum with Bruker 
WINEPR simulation package because the peaks are very broad making direct reading difficult. The A|| value of the 
“shoulder” component at pH 5.5 was roughly estimated because the second peak was not well-defined. 
 
ESR spectra were obtained for Cu(II) ion in presence of TRH at pH 5.5, 7.45, 9.0 and 
10.76. A|| and g|| values were extracted. As shown in Figure 2 and Table 3-2, the main binding 
mode at pH 5.5 is OOOO. There is a minor component other than OOOO at slightly higher field. 
Due to the ambiguity of the second peak, it is difficult to assign any binding mode to this 
component. Based on the position of the first peak, one nitrogen binding is estimated. From 7.45 
to 10.76, the Cu(II) ion hyperfine structure did not change significantly, suggesting the same 
equatorial binding. Shown in Table 3-2, the A|| and g|| values for all these pH values very well fit 
the NNNO binding mode. These results also are in good agreement with the visible 
spectroscopic data.  
57 
 Table 3-2. ESR and UV-Vis parameters for Cu(II) signals in presence of TRH at different pH values. 
pH A|| (G) g|| λmax a (nm) Equatorial binding 
5.5 121 ± 2 2.41 ± 0.01 743 OOOO 
7.45 178 ± 2 2.26 ± 0.01 589 NNNO 
9.0 178 ± 2 2.26 ± 0.01 590 NNNO 
10.76 175 ± 5 2.27 ± 0.01 586 NNNO 
a pH 6.24, 7.01, 8.97 and 11.01, respectively. 
 
Potential nitrogen donors in the TRH molecule include one lactam nitrogen from the 
pyroglutamyl residue, 1-N (pyridine) and 3-N (pyrrole) of the imidazole ring, two amide 
nitrogens from the two peptide bonds, and one amide nitrogen at the blocked C-terminus. The 
oxygen donor could be any one of the carbonyls, a water or a hydroxide. As mentioned above, 
the Pro residue does not seem to take part in the coordination. The tertiary amide is a weak donor. 
Furthermore, the nitrogen lone pair and the carbonyl group should be in the same plane [20]. 
This is extremely difficult for a prolinyl amide. As for the C-terminal amide, formation of a 5- or 
6-membered fused ring structure does not seem possible. At the same time, the spectroscopic 
properties of TRH, deHPro3-TRH and TRH-OH are very close to each other. All the above 
argue against the participation of Pro in the binding. Despite all this, TRH does not act as a di-
peptide. It forms a 1:1 complex with Cu(II) ion with three nitrogen donors, as do tripeptides. The 
His residue is known to have an electron-rich side-chain that can act as metal ligand [26,34,35]. 
If we do not consider Pro as having a donor, the three nitrogen donors are possibly the 1-N of 
imidazole, the lactam nitrogen of pGlu, and the amide nitrogen between the pGlu and His 
residues. 
 In general, biuret coordination starts at the N-terminal amine nitrogen of the peptide. The 
peptide amide bonds undergo deprotonation following that to form stable fused ring structures 
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 [20,21]. In a TRH molecule, there is no amine group. The C-terminus, known to play a role when 
the N-terminus is blocked [36], is also blocked. It is of interest to find out how the coordination 
starts in a peptide with both termini blocked. 
Selective broadening of proton and carbon resonances of ligands in NMR spectroscopy 
by a paramagnetic metal ion, such as Cu(II), can help locate the binding sites. Such ions increase 
fluctuations in the local magnetic field and reduce the both the longitudinal (T1) and transverse 
(T2) relaxation times of other nuclei nearby [37], thus altering their NMR signals. As line width 
is proportional to T2-1, an affected signal could be broadened and shortened, or even eliminated 
depending on the magnetic ion concentration [38]. By comparing the NMR spectra of ligands in 
the presence and absence of metal ion, one can deduce the most-affected protons or carbons in 
the ligand molecules. In a selective broadening experiment, the metal ion is usually held at 
1/1000 or less of the ligand concentration. For peptide complexes in basic solutions, however, 
the binding at this molar ratio is very often not the same as at stoichiometric conditions. The 
main reason is that the relatively rare Cu(II) ions associate with and dissociate from the peptides 
rapidly before any peptide amide deprotonation or ring closure occurs [39]. In other words, the 
peptide acts as a monodentate ligand. The NMR signal changes under this condition will only 
indicate where the coordination begins, as the N-termini of glycyl di- or tri- peptides [40]. 
Figure 3-3 shows the 1H NMR spectra of intact TRH and Cu(II)-titrated TRH solutions. 
Assignments of the peaks in both spectra required the TRH spectra of 1H-1H 2-D, 1H-13C 2-D 
NMR and DEPT (Distortionless Enhancement by Polarization Transfer, which records 13C 
spectra that are edited with respect to the number of protons directly bonded to the carbons). As 
shown in Figure 3-3B, the imidazole protons respond most sensitively, showing signs of 
broadening and lowering when Cu(II) is present at only 1/4000 equivalents of TRH. This result 
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 suggests that the imidazole acts as the initiating site during the binding, analogous to the primary 
–NH2 group in most peptides. The two nitrogen atoms are both good donors, while the 1-N does 
have the advantage to form 6-membered ring structure. Therefore, 1-N is thermodynamically 
favored. 
 
 
 
A 
 
B 
 
Figure 3-3. 1H NMR spectra of TRH in absence and presence of Cu(II) ion.. 
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 To sum up, the NNNO binding is a reasonable structure and consistent with experimental 
data. Amide deprotonation propagates along the peptide backbone toward pGlu residue once the 
1-N of imidazole coordinates with Cu(II). As for the fourth donor, the oxygen, Billo’s equation is 
not able to distinguish a carbonyl, water or hydroxide. The computational software CAChe 
helped to verify the feasibility of some possible structures and to exclude some. The structure 
with a carbonyl oxygen either from the His-Pro peptide bond or from the C-terminal amide 
yielded structures with no reasonable Prolyl C-terminal carbonyl bond length or reasonable 
tetragonal complex structure. The fourth donor has to be a water or a hydroxide from this point 
of view. Figure 3-4 is an optimized structure by CAChe. The four donors are the deprotonated 
pGlu lactam nitrogen, the deprotonated pGlu-His peptide amide nitrogen, the His 1-N and H2O. 
Cu(II)-peptide biuret complexes are square planar [41,42]. The two axial water ligands are 
placed 3 Å from Cu(II). Atoms at this distance hardly affect the spectra. The simulation also 
suggested that there may be a hydrogen bond between the C-Terminal amide carbonyl oxygen 
and the equatorial water proton. 
 
Figure 3-4 . CAChe simulation of Cu(II)-TRH complex of NNNO binding mode.  
Structure was optimized by the beautify function on valence, hybridization and geometry. The 1.763 (Å) labels the 
O-H distance of a possible hydrogen bond. 
61 
 3.4.3. The effect of pH 
As deprotonation is a crucial step in Cu(II) and peptide binding, the pH of the solution is 
expected to affect significantly the complex formation. Figure 3-5 shows the band shift with 
increasing pH of Cu(II)-TRH in borate buffers. From the Job’s plots and ESR results at various 
values of pH, we acquired the knowledge that in buffered systems, TRH starts to bind Cu(II) ion 
in an NNNO mode at pH slightly over 7.0. At least through pH 10.8 the equatorial binding mode 
is always NNNO. There is no evidence for NNOO binding. The pH range for existence of an 
NNOO binding mode, if there should be one, is expected to be very narrow, within pH 6 – 7. 
This likely results from the cooperativity in the serial binding of the three nitrogen donors.  
 
 
Figure 3-5. Band shift of Cu(II)-TRH with increasing pH in borate buffer. 
Dashed lines define the following wavelength ranges:  
A - NNNO (one imidazole, two deprotonated amides, one water or hydroxide);  B - NNNN (two imidazoles, two 
deprotonated amides);  C - NNNN (one imidazole, three deprotonated amides). 
 
There are signs of multiple TRH binding at lower pH. The histidine is a basic residue. 
The pKa of protonated imidazole has reported values ranging from 6.0 to 7.1 [43,44]. In about 
neutral solutions with Cu(II) present, one of the two imidazole nitrogens undergoes 
deprotonation and binds Cu(II). In this way the TRH acts as a monodentate ligand. This possibly 
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 accounts for the donor in non-buffered solutions, in which one Cu(II) ion binds four TRH 
molecules. From a steric aspect, this seems easier for the 3-N (pyrrole). The non-buffered Job’s 
experiment of one of the analogs, MeHis2-TRH, should differentiate the two imidazole nitrogens. 
The MeHis2-TRH molecule bears a methyl group at the 3-N. As a monodentate ligand, the only 
available nitrogen donor is the imidazole 1-N. If the His 1-N sees substantial steric hindrance, 
this analog would not bind Cu(II).  
 
 
Figure 3-6. Job’s plots of Cu(II)-TRH and Cu(II)-MeHis2TRH in non-buffered solutions. 
The perpendicular line indicates Cu(II) fraction 0.20, which corresponds for Cu(II):peptide = 1:4.  
 
The Job’s experiment with MeHis2-TRH yielded a similar plot as the one with TRH (see 
Figure 3-6). The λmax was 590 nm. The apparent stoichiometry was about 1:4, too. Obviously the 
1-N of His imidazole is capable of binding Cu(II). The apex of MeHis2-TRH plot was lower 
than that of TRH. The apparent binding constant for MeHis2-TRH in this case is smaller than 
that of the native peptide. At this point, we are not able to identify the nitrogen donor when TRH 
acts as a monodentate ligand. It could be either the 1-N or the 3-N of the imidazole. Figure 3-7 
shows the CAChe simulation of Cu(II)-(TRH)4 (via imidazole 3-N) and Cu(II)-(MeHis2-TRH)4 
(via imidazole 1-N). The relative stabilities of the two divalent complex ions are indicated by 
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 their “current energy” calculated by CAChe of the optimized structures. The two numbers are 
only a few percent different. They show relatively equal stability. 
 
 
 
Figure 3-7. CAChe simulation of Cu(II)-TRH4 and Cu(II)-(MeHis2TRH)4. 
TRH binds Cu(II) at imidazole 3-N. MeHis2TRH binds Cu(II) at imidazole 1-N. The listed energy values were 
“current energy” of geometry and hybridization beautified structures. 
 
The pH 7.10 Job’s plot reveals a mixture of 1:1 stoichiometry and complexes with higher 
peptide:Cu(II) ratios. At pH 7.45 the 1:1 complex predominates. This means that in the presence 
of Cu(II) the pKa of the two amides is not much higher than that of the imidazole. The 1:1 and 
1:4 binding modes give very close λmax values: 588 nm for the 1:1 binding and 592 nm for the 
1:4 binding. One would deduce that for any transitional binding mode between these two the 
absorption band is within the range of 588 – 590 nm. This is why the Cu(II)-TRH d-d band does 
not shift significantly with increasing pH from 7.01 to 11.01 (< 10 nm when Cu(II) and TRH 
were at 1:1 molar ratio, Figure 3-5).  
As pH further increases to over 12.0 the band shifts to 564 nm. This sharp shift of 
absorption band indicates deprotonation. There are two possible deprotonations that could cause 
band shifting: 1) deprotonation of an amide, which binds Cu(II) as the fourth donor;  2) 
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 deprotonation of the 3-N (pyrrole) of the imidazole, which may or may not bind Cu(II). 
Hypothesis 1 was invalidated by CAChe simulation. The only available amide, the C-terminal 
amide is not able to reach the equatorial position while keeping reasonable bond angles and 
lengths. For hypothesis 2, Cu(II)-binding-facilitated proton loss from an imidazole pyrrole 
nitrogen has been reported widely. It has been reported to occur at various pH values depending 
on the actual ligand structure, as low as pH 9.6 in some cases with TRH [45,46]. The 
deprotonated pyrrole nitrogen of imidazole may or may not coordinate with Cu(II) ion [44,47]. 
However, shown by Figure 3-8, all the five His-containing TRH-like peptides including MeHis2-
TRH which is not capable of pyrrole deprotonation display very similar pH-dependent band-
shifting. This is a strong evidence against hypothesis 2. For TRH the pyrrole nitrogen 
deprotonation is still possible and consequently may lead to polymerization of Cu(II)-TRH [45] 
(but the stoichiometry will still be 1:1). However, this deprotonation is not the main cause of the 
band shifting at high pH. 
 
 
Figure 3-8. Band shift of Cu(II) complexes of TRH analogs with increasing pH. 
Only His-containing analogs were included. All solutions were in borate buffer. 
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 Another possible deprotonation is the deprotonation of the equatorial water, or 
replacement of the water by a hydroxide. Billo did not distinguish the contributions of carbonyl, 
water or hydroxide oxygen in his equation [29]. In a later regression by Sigel and Martin, the 
three types of oxygen donors also had the same contribution to Cu(II) complex absorption [30]. 
While the above two set of factors agree closely and work relatively well on general Cu(II) 
complexes of nitrogen-containing ligands, attention should be drawn to the generally different 
donating abilities of the three oxygen donors, especially the water which is a known weak donor 
compared to the other two. Prenesti et al. [48] studied over 100 Cu(II) complexes and came up 
with refined factors. Important to their discussion, they found a bigger contribution from 
carbonyl and hydroxide (0.39), while their factor for water is in agreement with Billo and Sigel 
and Martin (0.296). Our absorption data of [Cu(OH-)4]2- (see Table 3-1) gives a factor of 0.391 
for OH- in this complex in agreement with Prenesti et al. The increased contribution factor of 
hydroxide shifts the calculated Cu(II)-TRH band (NNN(OH-)) to 553 nm. This deprotonation of 
water ligand does not depend on the actual peptide structure, which is consistent with Figure 3-8. 
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 3.5. Conclusions 
TRH and its analogs lack a primary amine group which is generally the initiating site of 
coordination with Cu(II) ion. In TRH, the imidazole nitrogen initiates complexation. 
Coordination of Cu(II) ion and TRH starts from 1-N of the imidazole and proceeds along the 
peptide backbone toward the N-terminus, involving the deprotonated amide between pGlu and 
His, and the deprotonated lactam amide in the pGlu residue. A water molecule completes the 
ligand set. Binding in this way occurs at pH as low as 7.10 in buffered systems. There should be 
considerable Cu(II)-TRH interaction under physiological conditions (pH 7.4), which may affect 
TRH-receptor interaction. The 1:1 stoichiometry is expected to predominate at physiological 
concentrations of Cu(II) and TRH. 
67 
 ACKNOWLEDGEMENTS 
 
This work was funded by the National Institutes of Health grant GM44842. Dr. Marco 
Bonora has provided great help with ESR data acquisition. 
The published paper was dedicated to Prof. Rex Shepherd for his many enthusiastic and 
insightful comments and discussion on inorganic chemistry. 
68 
  
BIBLIOGRAPHY 
 
[1]. Kastin, A. J.; Ehrensing, R. H.; Schalch, D. S.; Anderson, M. S. Lancet 1972, 2, 740-742. 
[2]. Prange, A. J., Jr.; Breese, G. R.; Cott, J. M.; Martin, B. R.; Cooper, B. R.; Wilson, I. C.; 
Plotnikoff, N. P. Life Sci. 1974, 14, 447-455. 
[3]. Prange, A. J., Jr.; Lara, P. P.; Wilson, I. C.; Alltop, L. B.; Breese, G. R. Lancet 1972, 2, 
999-1002. 
[4]. Winokur, A.; Utiger, R. D. Science 1974, 185, 265-267. 
[5]. Winokur, A.; Utiger, R. D. Thyrotropin-releasing hormone in the central nervous system: 
distribution and degradation. in Cent. Nerv. Syst. Eff. Hypothal. Horm. Other Pept., 
[Symp.]. 1979: Raven, New York. 
[6]. Bird, J. A.; Clarke, L.; Symonds, M. E. Biol. Neonate 1998, 73, 52-59. 
[7]. Hashimoto, T., Yoneda, M., Kojima, K., Murohisa, T., Tamano, M., Iijima, M., Shimada, 
T., Sugaya, H., Terano, A., Tamori, K., Nakade, Y., Yokohama, S., Nakamura, K., and 
Makino, I. Jpn. Pharmacol. Ther. 2001, 29, s189-s192. 
[8]. Yamada, M.; Monden, T.; Satoh, T.; Satoh, N.; Murakami, M.; Iriuchijima, T.; Kakegawa, 
T.; Mori, M. Biochem. Biophys. Res. Commun. 1993, 195, 737-745. 
[9]. Perlman, J. H.; Laakkonen, L.; Osman, R.; Gershengorn, M. C. J. Biol. Chem. 1994, 269, 
23383-23386. 
[10]. Perlman, J. H.; Thaw, C. N.; Laakkonen, L.; Bowers, C. Y.; Osman, R.; Gershengorn, M. 
C. J. Biol. Chem. 1994, 269, 1610-1613. 
[11]. Laakkonen, L. J.; Guarnieri, F.; Perlman, J. H.; Gershengorn, M. C.; Osman, R. 
Biochemistry 1996, 35. 
69 
 [12]. Ogawa, N.; Mizuno, S.; Kishimoto, T.; Mori, A.; Kuroda, H.; Ota, Z. Neurosci. Res. 1984, 
1, 363-368. 
[13]. Formicka-Kozlowska, G.; Kozlowski, H.; Jezowska-Trzebiatowska, B.; Kupryszewski, G.; 
Przybylski, J. Inorg. Nucl. Chem. Lett. 1979, 15, 387. 
[14]. Yamada, Y.; Nakasuka, N.; Tanaka, M. Inorg. Chim. Acta 1991, 185, 49-56. 
[15]. Chen, J.-G.; Woltman, S. J.; Weber, S. G. J. Chromatogr. A 1995, 691, 301-315. 
[16]. Warner, A. M.; Weber, S. G. Anal. Chem. 1989, 61, 2664-2668. 
[17]. Meng, R.; Xia, W.; Sandberg, M.; Stephens, R.; Weber, S. G. submitted to J. Chromatogr. 
A 2004. 
[18]. Lii, J. H.; Allinger, N. L. J. Am. Chem. Soc. 1989, 111, 8576-8582. 
[19]. Lii, J.-H.; Allinger, N. L. J. Comput. Chem. 1998, 1998, 9. 
[20]. Margerum, D. W. Pure Appl. Chem. 1983, 55, 23-34. 
[21]. Margerum, D. W.;  Wong, L. F.;  Bossu, F. P.;  Chellappa, K. L.;  Czarnecki, J. J.;  
Kirksey, S. T., Jr.;  Neubecker, T. A. Adv. Chem. Ser. 1977, 162, 281-303. 
[22]. Bataille, M.;  Formicka-Kozlowska, G.;  Kozlowski, H.;  Pettit, L. D.;  Steel, I. J. Chem. 
Soc. Chem. Commun. 1984, 4, 231-232. 
[23]. Formicka-Kozlowska, G.;  Kozlowska, H.;  Siemion, I. Z.;  Sobczyk, K.;  Nawrocka, E. J. 
Inorg. Biochem. 1981, 15, 201-212. 
[24]. Tonoue, T.;  Minagawa, S.;  Kato, N.;  Kan, M.;  Terao, T.;  Nonoyama, K.;  Ohki, K. 
Pharmacology Biochemistry and Behavior 1979, 10, 201-204. 
[25]. Formicka-Kozlowska, G.; Bezer, M.; Pettit, L. D. J. Inorg. Biochem. 1983, 18, 335-347. 
[26]. Farkas, E.; Sovago, I.; Kiss, T.; Gergely, A. J. Chem. Soc. Dalton Trans. 1984, 611-614. 
[27]. Hanig, R. C.; Aprison, M. H. Anal. Biochem. 1967, 21, 169-177. 
70 
 [28]. Andrasi, E.; Farkas, E.; Scheibler, H.; Reffy, A.; Bezur, L. Arch. Gerontol. geriat. 1995, 
21, 89-97. 
[29]. Billo, E. J. Inorg. Nucl. Chem. Lett. 1974, 10, 613-617. 
[30]. Sigel, H.; Martin, R. B. Chem. Rev. 1982, 82. 
[31]. Burns, C. S., Aronoff-Spencer, E., Dunham, C. M., Lario, P., Avdievich, N. I., Antholine, 
W. E., Olmstead, M. M., Vrielink, A., Gerfen, G. J., Peisach, J., Scott, W. G., and 
Millhauser, G. L. Biochemistry 2002, 41, 3991-4001. 
[32]. Aronoff-Spencer, E.; Burns, C. S.; Avdievich, N. I.; Gerfen, G. J.; Peisach, J.; Antholine, 
W. E.; Ball, H. L.; Cohen, F. E.; Prusiner, S. B.; Millhauser, G. L. Biochemistry 2000, 39, 
13760-13771. 
[33]. Peisach, J.; Blumberg, W. E. Arch. Biochem. Biophys. 1974, 165, 691-708. 
[34]. Boka, B.; Myari, A.; Sovago, I.; Hadjiliadis, N. J. Inorg. Biochem. 2004, 98, 113-122. 
[35]. Sovago, I.; Farkas, E.; Bertalan, C.; Lebkiri, A.; Kowalik-Jankowska, T.; Kozlowski, H. J. 
Inorg. Biochem. 1993, 51, 715-726. 
[36]. Shi, F.; Woltman, S. J.; Weber, S. G. Anal. Chim. Acta 2002, 474, 1-9. 
[37]. Bertini, I.; Luchinat, C. Coord. Chem. Rev. 1996, 150, 77-110. 
[38]. Emsley, J. W.; Feeney, J.; Sutcliffe, L. H., High Resolution NMR Spectroscopy, ed. J.W. 
Emsley; J. FeeneyL.H. Sutcliffe. Vol. I. 1965, New York: Pergamon Press, Ltd. 
[39]. Espersen, W. G.; Martin, R. B. J. Am. Chem. Soc. 1976, 98, 40-44. 
[40]. Li, N. C.; Scruggs, R. L.; Becker, E. D. J. Am. Chem. Soc. 1962, 84, 4650-4654. 
[41]. Nolan, K. B.; Soudi, A. A.; Hay, R. W. Amino Acids, Peptides, and Proteins 1994, 25. 
[42]. Nolan, K. B.; Soudi, A. A.; Hay, R. W. Amino Acids, Peptides, and Proteins 1996, 27, 282-
332. 
71 
 [43]. Grant, G.; Ling, N.; Rivier, J.; Vale, W.; Butcher, M.; Hewitt, W. Biochemistry 1972, 11, 
3070-3073. 
[44]. Sundberg, R. J.; Martin, R. B. Chem. Rev. 1974, 74, 471-517. 
[45]. Morris, P. J.; Bruce Martin, R. J. Inorg. Nucl. Chem. 1971, 33, 2913-2918. 
[46]. Osz, K.; Varnagy, K.; Suli-Vargha, H.; Sanna, D.; Micera, G.; Sovago, I. Dalton Trans. 
2003, 10, 2009-2016. 
[47]. Aiba, H.; Yokoyama, A.; Tanaka, H. Bull. Chem. Soc. Jpn. 1974, 47, 1437-1441. 
[48]. Prenesti, E.; Daniele, P. G.; Prencipe, M.; Ostacoli, G. Polyhedron 1999, 18, 3233-3241. 
 
72 
 4. The Rotating Ring-Disk Electrochemistry of Copper Complexes of  
Thyrotropin-releasing Hormone 
73 
 4.1. Abstract 
The C- and N-termini blocked neuropeptide Thyrotropin-releasing Hormone (TRH) 
forms electroactive Cu(II) complex. Rotating ring-disk electrode (RRDE) acts as a powerful tool 
in investigating the reversible electrochemistry of the Cu(III)/Cu(II) couple as complex of TRH 
in alkaline solution. Oxidation occurs on the disk electrode and reduction on the ring electrode. 
Varying rotation frequency helps to discover chemical kinetics associated with the 
electrochemistry. The plot of limiting current vs. square root of rotation frequency deviates from 
theoretical Levich’s equation, indicating preceding chemical reactions. The deviation is more 
pronounced at higher initial concentration. A non-electroactive complex, dimer Cu(II)2-TRH2, is 
postulated. Simulation of RRDE behavior of the postulated Cu(II)-TRH system by DigiSim 
software has succeeded in matching experimental data. Capillary electrophoresis implies 
negative charge on the dimer. It is suggested that an hydroxo-bridge may link the two Cu(II) 
centers. CAChe program proves that the bi-nuclear Cu(II)2-TRH2 complex is possible. 
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 4.2. Introduction 
 
The selective chromatographic detection of peptides has been established based on the 
reversible electrochemistry of the Cu(III)/Cu(II) couple in polydentate peptide complexes [1,2], 
also called biuret complexes. In support of this detection method, the RRDE has been used to 
study the electrochemical kinetics of Cu(II) complexes of oligoglycines as model peptide ligands 
[3]. The results revealed effects of pH, buffer and rotation frequency on the electrochemistry of 
Cu(II)-oligoglycine complexes. While oligoglycine complexes serve to teach us about the 
essential chemistry of the peptide backbone with Cu(II), their study is not sufficient to teach the 
complexities of bioactive peptides. Additional features in peptide structures including side chains 
and modified termini add complexity to the coordination reactions and thus the electrochemical 
kinetics of the complexes. 
 
 
Figure 4-1. TRH molecule. 
It is neutral  at pH 9.8. 
 
Thyrotropin-releasing Hormone (TRH), or pyroglutamyl-histidyl-prolyl amide, is a 
tripeptide blocked at both C- and N-termini (the termini are both amides). TRH has been shown 
to improve functional recovery after neurologic dysfunctions, such as brain trauma and epilepsy, 
in both humans and animals such as rats, mice and cats [4-8]. We believe that, coupled with 
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 online microdialysis and preconcentration, the concentration of TRH can be monitored. Further, 
the unique structure of TRH makes it interesting from a coordination chemistry and 
electrochemistry perspective. The probable structure of Cu(II)-TRH has been determined by 
spectroscopic and electrochemical means [9]. Briefly, Cu(II) binds to TRH through the pGlu 
amide nitrogen, the pGlu-His peptide bond nitrogen, the 1-N of the His imidazole and a water. 
The electrochemistry of Cu(II)-TRH is much more complicated than that of the Cu(II)-
polyglycines. This chapter reports on the electrochemistry of the Cu(II) complex of TRH. 
The rotating ring-disk electrode (RRDE) has proven to be powerful in studies of 
homogeneous kinetics and equilibria [10], and is particularly suited to modeling dual electrode 
detection [3]. The disk electrode serves as the anode and the ring electrode as the cathode. The 
flow pattern introduced by the rotation of the electrode draws solutes first over the central disk 
electrode and then over the ring electrode. The disk electrode signal obtained for a simple, mass 
transport-limited electron-transfer process obeys the Levich equation [10]:  
2/16/13/2*620.0/* ωνδ −== DnFACnFADCiD    Eq. (4-1)
where iD (disk current) is in mA, C* (concentration of the analyte) is in M, D (diffusion 
coefficient of the solute) is in cm2/s, ν (kinematic viscosity of the solution) is in cm2/s, ω 
(rotation frequency) is in rad/s, n is the number of electrons transferred per molecule of solute, 
and F is the Faraday constant. The ratio of current at the ring to current at the disc is known as 
the collection efficiency, N0.
Homogeneous chemical reactions preceding and following the disk electrode reaction 
affect the current profile vs. rotation frequency. The model biuret complex tetraglycine, 
decomposes following oxidation [11]. The effect of this ECE (electrochemical-chemical-
electrochemical) process is seen from extra disk current and reduced ring current at low rotation 
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 frequencies. Preceding reactions (CE) include amide deprotonation or ligand exchange [3]. They 
often cause lower current than expected at high rotation frequencies. For simple peptides such as 
G4 and G5, these effects can be eliminated by choosing the right pH and buffer systems to obtain 
a plot of limiting current vs. ω1/2 that obeys the Levich equation [3].  
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 4.3. Experimental 
4.3.1. Chemicals 
Thyrotropin-releasing hormone from Bachem (King of Prussia, PA, USA) was used 
without further purification, but the purity (96%) was taken into account in solution preparation. 
Copper sulfate pentahydrate (J.T. Baker, Phillipsburg, New Jersey, USA) was re-crystallized 
once from water. Borate buffers were all prepared in 0.25 M KNO3 (J.T. Baker, USA) with 
Na2B4O7⋅10H2O from Sigma (St. Louis, MO, USA). In pH effect experiments, the borate 
concentration was 0.10 M. In all other experiments using borate, the borate concentration was 
0.05 M. All pH values were adjusted with 0.40 M boric acid (EM science, Gibbstown, NJ, USA) 
and/or 4 M NaOH (EM science), and measured with an Accumet® pH-meter (Fisher Sci, 
Fairlawn, New Jersey, USA), standardized before each use. Copper-peptide solutions were 
prepared by diluting a desired amount of stock solution in the order of peptide then copper 
sulfate in buffer. Molar ratios were 1:1 unless mentioned. 
All water used was from a Milli-Q A10 Synthesis water purification system (Millipore, 
Billerica, Massachusetts, USA). 
4.3.2. Instruments and procedures 
The rotating ring-disk apparatus consisted of a DT-29 glassy carbon/glassy carbon ring-
disk electrode, an ASR-2 analytical rotator, and an RDE-3 potentiostat (all from Pine Instrument 
Co., Grove City, PA, USA). The ring-disk electrode has a disk area of 0.2475 cm2, and 
geometric collection efficiency of 0.3714. A platinum grid counter electrode and a Ag/AgCl 
reference electrode (3 M NaCl, Bioanalytical Systems, West Lafayette, Indiana, USA) were used. 
All potentials here are reported relative to this reference electrode. Before each run the working 
electrodes were wet polished with 0.05 µm γ-alumina powder (Buehler Ltd., Lake Bluff, Illinois, 
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 USA) and rinsed with Milli-Q deionized water from a wash bottle. The electrode was then placed 
in the rotator. Background current (buffer used for the sample solution) was measured first and 
subtracted from sample signal. 
The potentiostat signals were filtered with a WaveTek 852 filter (WaveTek, San Diego, 
CA, USA) set for low pass with 1 Hz cutoff frequency. RRDE data were collected using 
EzChrom chromatography software with a DT2802 chromatography board (Data Translation, 
Inc., USA), or PeakSimple software with a SRI202 board (SRI Instruments, Torrance, CA, USA). 
Data collection was triggered manually while the voltage was simultaneously applied to the 
electrode. All files then were converted to ASCII format and processed with Excel. 
For hydrodynamic voltammetry, the disk potential was swept linearly from 0 mV to 1000 
mV. The sweep rate was always 0.5 V/min unless otherwise specified. The ring electrode was 
maintained at a constant potential of 0 mV. RRDE rotation frequency studies were conducted 
with the disk electrode potential held at 900 mV and the ring electrode at 0 mV. These potentials 
were identified by voltammetry as being in the limiting current region. In each run, the electrode 
was rotated initially at a moderate rotation frequency before potentials were applied. The non-
Faradic current was permitted to decay no less than 2.5 min. The rotation frequency then was 
varied in a random sequence with some of them repeated 1 or 2 times. Data collected within the 
initial period of current decay were ignored. The rotation frequency was maintained at each 
value long enough to ensure steady state. 
The mass transport properties of the system were tested from 10 to 5000 rpm using 0.20 
mM ruthenium(III) hexamine trichloride (Aldrich, Milwaukee, WI, USA) as a reversible one-
electron standard. The solution was prepared in 0.4 M carbonate buffer, pH 9.8. The complex 
was reduce at the disk (Eapp = -280 mV) and then oxidized at the ring (Eapp = 0 mV). Data 
79 
 yielded a linear Levich plot (R2 = 0.9945, n = 39) over the entire rotation frequency range tested 
at both disk and ring electrodes. The diffusion coefficient obtained, 4.05 ×10-6 cm2/s, agreed with 
the value 3.91×10-6 cm2/s obtained by the Taylor-Aris flow injection method. 
Spectroscopic measurements employed an HP 8453 spectrophotometer with HP 8453E 
operating software (Agilent, USA). Spectra of copper – peptide complexes in 1 cm quartz 
cuvettes were measured over 400 – 1100 nm in general scanning mode at 0.5 s integration time, 
using Milli-Q water as a solvent blank in all cases.  
Room temperature was 22 ± 2 °C during all RRDE experiments. 
Determination of diffusion coefficients by laminar flow axial dispersion was according to 
the procedure of A. Beisler [Beisler, 2003 #14]. Briefly, a rectangular plug of solute is allowed to 
disperse in a 25 µm inside diameter capillary under pressure-induced flow. Analysis of the shape 
of the formerly rectangular zone as it passes through a downstream detector yields the diffusion 
coefficient. The aqueous flow solution containing 0.1% trifluoroacetic acid, 3% 1-propanol and 
25% acetonitrile was pumped with a Waters 600 E quaternary pump. A splitter tee was used to 
decrease the flow rate to 2-5 µL/min. The TRH stock solution was diluted in mobile phase to 
make a concentration of 10 µM and injected with an Upchurch microinjector. After the injector 
the biuret solution containing 5.00 mM CuSO4, 30.0 mM sodium tartrate in 1.2 M carbonate 
buffer was combined with flow solution mentioned above through a home-designed micromixer. 
The analyte was detected at 0.80 V versus Ag/AgCl with a 10 µm carbon fiber electrode 1 mm in 
length (CV-27 Potentiostat, BAS, W. Lafayette, IN, USA) and current was measured with a 
Keithly (Cleveland, OH) 427 Picoammeter. Signals from the ammeter were collected at 50 Hz by 
EzChrom (Scientific Software, San Ramon, CA). Data obtained were exported and smoothed 
using PeakFit software. The first derivative was determined in PeakFit using Savitzky-Golay 
80 
 filtering. The statistical moments were determined by fitting the 5-parameter GEMG function to 
the data based on the least squares criterion.  
The obtained diffusion coefficient of the Cu(II)-TRH complex was then corrected for 
solvent based on Scheibel Correlation [23]. The diffusion coefficient in aqueous solution is 5.86 
×10-6 cm2/s. This value is used in the Levich equation to determine the expected current response 
for a diffusion controlled one-electron transfer reaction of the Cu-TRH complex. 
Capillary electrophoresis experiments were carried out on an ISCO 3850 Capillary 
Electropherograph (ISCO Inc., Lincoln, NE), with PeakSimple Chromatography Data System 
with a SRI202 board (SRI Instruments Inc., Torrance, CA, USA) for data collection. The UV 
detector was set at either 210 nm or 590 nm. The fused silica capillary (Polymicro Tech, LLC. 
Phoenix, Arizona, USA) had a 50 µm inner diameter and 70 cm total length. Detecting window 
was 50 cm from the injecting port. A voltage of 20 kV ran through 50 mM pH 9.84 borate buffer. 
Sample solutions of 1.0 mM each Cu(II) and peptide prepared in the running buffer were 
vacuum-injected for 5 sec each run. ACN of 5% (v/v) served as a neutral marker. 
4.3.3. Simulation. 
Molecular simulation was carried out with the software CAChe (Fujitsu, Ltd., Japan) 
version 6.1.1. Structures were first checked for correct valences and hybridizations, then 
optimized using Allinger’s standard MM3 force field model [15]. The following factors were 
taken into account when optimizing: bond stretch, bond angle, dihedral angle, improper torsion, 
van der Waals interaction, electrostatics interaction, hydrogen bond, torsion stretch, and bend-
bend interactions.  
Electrochemical simulation was carried out with software DigiSim (BAS, USA), version 
3.03b, under hydrodynamic conditions. 
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 4.4. Results and discussion 
In pH 9.84 borate buffers, equimolar solutions of Cu(II) and TRH show a characteristic 
bluish-purple color, with a maximum absorbance (λmax) at 588 nm. The voltammetric wave 
generated by RRDE gives a half-wave potential, E1/2, of 785 mV at both disk and ring electrodes. 
Shown in Figure 4-2, the same set of solutions displays different pH dependence in spectroscopic 
and electrochemical measurements. The absorption band does not shift in the range of pH 7.4 to 
pH 11 [9], while the E1/2 decreases linearly with a slope of -70 mV/pH. When either of the two 
reagents is in excess, the slope gets closer to -59 mV. 
 
 
Figure 4-2. pH-dependent spectroscopy and electrochemistry of 1:1 Cu-TRH. 
All solutions contain 1.00 mM (in spectroscopic measurements) or 0.10 mM (in electrochemical measurements) 
Cu(II) and TRH in borate buffers. Dashed horizontal lines in the left figure define the upper and lower limits of λmax 
for NNNO- and NNNN-bound Cu(II) calculated from Billo’s equation [16]. 
 
The potential shift with pH in Figure 4-2 shows a deprotonation-assisted redox reaction. 
The deprotonation is fast enough to catch up with the electron transfer. An example of not so fast 
deprotonation is that of the third peptide bond amide in Cu(II)-polyglycine complexes. The slow 
deprotonation causes two waves to be seen in RRDE voltammetry, representing two 
electroactive complexes Cu(II)-NNNO and Cu(II)-NNNN [3], the latter at a lower potential. The 
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 deprotonation in Cu(II)-TRH is clearly not this case. We determined earlier that the equatorially 
bound water may lose one proton and become a hydroxide ligand [9]. This deprotonation makes 
a promising candidate responsible for the potential shift with pH. Since this process is fast, we 
will not include it in discussing preceding reactions in the later part of this work. 
 
 
 
Figure 4-3. Experimental and predicted diffusion controlled currents plotted against ω . 1/2
Solution contains 1.00 mM each Cu(II) and TRH in pH 9.84 borate buffer.  
(a). Normalized currents. The upper trace is of disk signals, the bottom is of ring. Straight lines are predicted (D = 
5.86 ×10-6 cm2/s) from the Levich equation, taking the total concentration of Cu(II) ion as electroactive C*. (b). 
Experimental collection efficiency, calculated as iR/iD. (c). Apparent number of electrons involved in the redox 
reactions on disk and ring electrode. 
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 A Levich plot, in the case of a mass transport-limited oxidation, is a straight line with 
zero intercept. Figure 4-3a shows an experimental Levich plot of Cu(II)-TRH. It clearly deviates 
from the theoretical lines at both disk and ring electrodes. Figure 4-3b and 4-3c are replots of the 
same data. Figure 4-3b is the rotation frequency-dependent “experimental collection efficiency 
Nκ” obtained by dividing iD (limiting current at disk) by iR (limiting current at ring) at each 
rotation frequency. Figure 4-3c is the “apparent number of electrons transferred (ANE)” obtained 
by dividing each experimental current by the theoretical value.  
Based on rotation frequency, the data set can be divided into two parts. When rotation 
frequency is low (ω1/2 < 10 in the figure), Nκ is significantly less than No. Woltman et al. have 
shown similar RRDE behavior with Cu(II)-oligoglycines [3]. It is consistent with an ECE 
process recognized and studied by Margerum et al. [11]. Briefly, the Cu(III)-peptide as the 
product of the first electron transfer reaction decomposes and produces more oxidizable species. 
The irreversible oxidation of these species gives extra current at the disk and at the same time 
reduces the ring current because it removes available reactants for the ring electrode. 
Correspondingly, in Figure 4-3b Nκ is close to zero at low frequencies.  
When the rotation frequency is greater than 1000 rpm (ω1/2 > 10), ANE values of the disk 
and ring electrodes agree with each other, and Nκ reaches a plateau. Equal disk and ring ANE 
values and a constant Nκ represent a situation where little or no reaction occurs in the gap. Under 
this condition, all of the Cu(III) complex generated at the disk is reduced at the ring. The lifetime 
of the Cu(III) species depends on many things, one of which is substitution at the α-carbon in the 
amino acids making up the peptide. Glycines contribute to instability, while peptides from 2-
methylalanine (i.e., no α-hydrogens) have more stability [17-19]. For triglycine, the rotation 
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 frequency at which the plateau is reached is near 5000 rpm [3], greater than the value of 1000 
seen with Cu-TRH.  
As can be seen in Figure 4-3 (a and c), the number of electrons transfer at disk and ring 
electrodes agree with each other, but both are significantly smaller than 1 (Figure 4-3c). This 
behavior at high rotation frequencies is consistent with a CE (chemical-electrochemical) process. 
In such a process, the electroactive species is generated by a chemical reaction prior to the 
oxidation. As rotation becomes faster, less time is given for this reaction, so less reactant is 
provided to the disk electrode causing a lower disk current. Limiting current on an RRDE in this 
case is related to both K, equilibrium constant, and k, rate constant, of the preceding reaction. 
The value of K determines the fraction of electroactive species prior to the electric field 
application. The reaction’s relaxation time determines how rapidly the equilibrium responds to 
the electrochemical perturbation. 
The preceding reaction may have various origins. The Cu(II) and peptide binding 
equilibrium is the first to be considered. The conditional Cu(II)-TRH binding constant at pH 9.8 
has been estimated to be at least 105 M-1 [9]. It corresponds to 90% or more bound at 
concentrations of 1.0 mM each Cu(II) and TRH. This value is substantially bigger than the ANE 
values at high ω show in Figure 4-3c. This means if Cu-peptide binding equilibrium is the only 
preceding reaction, even at a infinitely small rate constant, the resulted limiting current should 
still be higher than the experimentally obtained value. There seems to be a reaction that takes 
away the already produced electroactive complex in bulk solution. We recorded limiting current 
data at various concentrations. The deviation of the experimental Levich plot should be more 
severe at lower concentrations if the binding equilibrium is mainly responsible for the deviation. 
As shown in Figure 4-4, the result is the opposite – there is less deviation at lower concentrations. 
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 At high rotation frequencies, the normalized limiting current decrease when concentration 
increases. Thus, we rule out the simple Cu-TRH binding as the preceding reaction. 
 
 
 
 
Figure 4-4. Concentration effect on RRDE behavior of 1:1 Cu(II)-TRH.  
All solutions are in pH 9.8 borate buffer. Dashed arrows indicate concentration increase. (a). Normalized currents. 
(b). Experimental collection efficiency, calculated by iR/iD. (c). Apparent number of electrons involved in the redox 
reactions on disk and ring electrode. 
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 Levich pointed out that with a first order preceding reaction, under conditions that 
(D/ν)1/6 << k/ω, the value i/ω1/2 is proportional to the value i and the Levich equation can be 
rewritten as [10]: 
)
61.1
(/ 2/16/1
6/1
2/1
2/1
Kk
Diii L νωω −=       Eq. (4-2) 
where iL is the limiting current without a preceding reaction, K is the equilibrium constant and k 
is the rate constant of the preceding reaction. Because of Cu(III)-TRH decomposition, for TRH 
only data representing a pure CE process (ω1/2 > 10, or ω > 1000) shall be used.  
Because Eq. (4-2) results from a first order process, the Kk1/2 value is a constant 
regardless of concentration. It can be determined from the slope of idisk/ω1/2 vs idisk. Our “Kk1/2” 
values calculated, however, vary with concentration. Figure 4-5 shows decreasing “Kk1/2” with 
increasing concentration. Apparently, the C in the case of Cu(II)-TRH is not a first order reaction. 
Eq. (4-2) does not work in this particular case. 
 
 
Figure 4-5. “Kk1/2” values decrease with increasing initial concentration.  
Values are derived from data in Figure 4-4 and Eq. (4-2). Cu(II):TRH = 1:1 
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 The data are consistent with a reaction that is higher order on the reactant side than the 
product side, in which the product is electroinactive. This hypothesis of higher order reaction is 
plausible and consistent with the electrochemical and spectroscopic data. However, neither 
visible spectroscopy nor electrochemistry is capable of verifying it. Spectroscopy cannot 
distinguish the two forms while electrochemistry only recognizes one of them. Thinking of the 
possible donor atoms in TRH, there is really no other nitrogen or carboxyl oxygen available due 
to steric tension. The proposed Cu(II)-TRH structure is a neutral species [9]. If the other complex 
form differs in the charge that the coordination core carries, capillary electrophoresis should tell 
more.  
We employed two TRH analogs (Figure 4-6) as comparison and charge reference. 
MeHisTRH and TRH-OH have the same amino acid sequence as TRH but each slightly different 
in one substituent. Their spectroscopic and electrochemical properties suggest identical 
equatorial binding under the current conditions [9]. TRH-OH and its complex should carry one 
more negative charge than the corresponding analogs due to the dissociation of the C-terminal 
carboxylic group. 
 
 
Figure 4-6. Sequences of TRH, TRHOH and Me-His2-TRH. 
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Both TRH and the 1:1 mixture of Cu(II) and TRH absorb maximally at 210 nm. The 
complex absorbs in the visible region while the peptide does not. In CE with ‘normal’ polarity, 
negatively charged species migrate at a lower velocity than the electroosmotic flow.  
 
 
 
Figure 4-7. CE signals of 1:1 TRH and Cu(II)-TRH mixture.  
In 50 mM pH 9.8 borate buffer. 1.0 mM each. Upper trace: detected at 210 nm. Bottom trace: detected at 590 nm. 
 
The top electrophorograms in Figure 4-7 show a peak for TRH (Cu(II) absent) at pH 9.8 
migrating with the migrating with the neutral marker (arrow). The “peak” for Cu(II)-TRH is 
complex. This is because we have injected a solution containing several components in an 
equilibrium, and the separation disturbs the equilibrium [20,21]. Krylov calls this ‘non 
equilibrium capillary electrophoresis of equilibrium mixtures’ or NECEEM. To interpret the data, 
it is helpful to consider the lower traces (λ = 590 nm). These traces show only Cu(II) complexes 
(note the lowest trace shows no response from TRH, and Cu(II) itself is not soluble at this pH). 
There is a small peak about 3.9 min corresponding to a neutral complex and a sharp peak at 4.25 
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 min as well as an exponentially decaying zone with a maximum at about 4.1 min. We interpret 
these curves within the framework of NECEEM [20,21]. The neutral Cu(II)-TRH complex gives 
a peak at 3.9 min. An anionic complex also exists with its peak at 4.25 min. The exponentially-
tailed peak in between represents the dissociation of the anionic complex to form the neutral 
complex.   
Complexes formed from MeHisTRH and TRH-OH give different CE traces (Figure 4-8). 
The TRH-OH complex should have a charge of -1, as does the peptide itself. The CE traces are 
completely consistent with this. The MeHisTRH complex acts like the TRH complex.  
 
 
 
Figure 4-8. CE signals of TRH, TRHOH and MeHisTRH and their copper complexes. 
All in 50 mM pH 9.8 borate buffer. All solutions contain 1.0 mM each Cu(II) and peptide.  
All detections are made at 210 nm. Arrows point to the neutral marker. 
 
Hence, there is a slow equilibrium involving two different forms of Cu(II)-TRH or 
Cu(II)-MeHisTRH complexes. One component of the equilibrium carries one extra negative 
charge. TRHOH, on the other hand, binds Cu(II) with overall charge unchanged.  
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 What proton is lost? Deprotonation of the N-terminal amide is first to be considered. 
Evidence for such deprotonation in a peptide is rare. The pKa of secondary amide is usually 
much higher than pH 10. Coordination to Cu(II) may promote the deprotonation, as for the 
peptide backbone amide deprotonation in a typical biuret reaction. The argument against it is 
there is no fused ring formation for the deprotonated N-terminal amide to bind Cu(II), while 
fused ring formation is essential in stabilizing a biuret complex. We conclude that deprotonation 
of N-terminal amide in TRH and MeHisTRH to introduce one negative charge to their Cu(II) 
complexes is not likely. The best possibility lies in the equatorial water ligand, which 
deprotonates to become a hydroxide. Another Cu(II) center may lose a water ligand and take the 
place of the missing proton in this hydroxide. 
We propose that a Cu(II)-TRH dimer exists, linked by an hydroxo-bridge. The presence 
of the dimer and the following reactions serve to explain the Levich plot curve shape of Cu(II)-
TRH systems and the electrophorograms, among which Eq. (4-4) embodies the preceding 
reaction that holds up the redox reaction on disk electrode: 
 
Cu(II) + TRH ? Cu(II)-TRH   
][)]([
])([
1 TRHIICu
TRHIICuK ⋅
−=   Eq. (4-3) 
kb1 
 
kf1
2Cu(II)-TRH ? (II)2-TRH2  
2
22
2 ])([
])([
TRHIICu
TRHIICu
K −
−=   Eq. (4-4) 
Cu(II)-TRH – e 
 
No simple sol
sought help from the  Cu
kb2 
kf2
= Cu(III)-TRH      Eq. (4-5) 
ution of Levich equation available under this particular condition. We 
simulation tool DigiSim to verify that a system following Eq. (4-3) – Eq. 
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 (4-5) behaves similarly as we observed for Cu(II)-TRH. The following parameters have been 
used in the simulation: 
1) Concentrations, electrode geometry, and voltammetry parameters are the same as in 
actual measurements. 
2) Diffusion coefficients (D): D of the electroactive form of Cu(II)-TRH complex 
(monomer) is 5.86 ×10-6 cm2/s;  those of Cu(III)-TRH and TRH are assumed the same;  
D of Cu(II)aq has been calculated to be 6.5 ×10-6 cm2/s based on the constant Dη/T = 2.23 
±0.37 ×10-10 cm2poise/Ks [22];  the value of 3.8 ×10-6 cm2/s has been used for Cu(II)2-
TRH2, an estimation based on the monomer value 5.86 ×10-6 cm2/s and the expression D 
∝ (molar volume)-0.6 [23], assuming that molar volume of the dimer is twice as that of the 
monomer. 
3) K1 (Eq. (4-3)) is about 105 M-1 [9]. Simulation trials were made within range 1 × 105 – 3 
× 105 M-1, and K2 (Eq. (4-4)) within the range 2 × 103 – 3.3 × 103 M-1. The two 
parameters were then narrowed down so that the unbound Cu(II) and TRH fractions were 
consistent with the spectroscopic data, and the simulated current matched experimental 
data. The values K1 = 1.0 × 105 M-1 and K2 = 2.8 × 103 M-1 are optimum. 
4) Reaction rate v = kf [reactant] – kb [product]. DigiSim simulation requires input of rate 
constant of the forward reaction kf, and calculates the backward rate constant based on 
equation K = kf/kb. We assign subscript 1 for parameters of Eq. (4-3) and subscript 2 for 
those of Eq. (4-4). Thus, reaction rate for Eq. (4-3) is v1 = kf1 [Cu(II)][TRH] – kb1[Cu(II)-
TRH], and reaction rate for Eq. (4-4) is v2 = kf2 [Cu(II)-TRH]2 – kb2[Cu(II)2-TRH2]. Our 
simulation of a simple binding equilibrium as the preceding reaction confirmed that kf1 
value from 10-3 to 105 M-1 s-1 only caused about 1% difference in the current at 0.06 mM 
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 Cu(II) and TRH each at 3000 rpm. So a value of 500 M-1s-1 has been chosen for kf1. The 
calculated value of kb1 is 0.005 s-1. 
5) All above parameters settled, optimal value of kf2 has been found to be 3.4×104 M-1s-1. 
The calculated value of kb2 is12.14 s-1.   
Figure 4-9 and Figure 4-10 compare simulated and experimental currents vs. 
concentration and rotation frequency. Final deviations (absolute(isim – iexp) shown are no more 
than 5%. Since the simulated currents match the experimental values rather well in the applicable 
concentration or rotation frequency range, we have demonstrated that a dimer complex of 
Cu(II)2-TRH2 is possible. 
 
 
Figure 4-9. Simulated and experimental currents of CE process vs concentration. 
Currents at 3000 rpm are plotted against varied concentration. Following Eq. (4-3) – Eq. (4-5):  
K1 = 1×105 M, kf1 = 500 M-1s-1, kb1 = 0.005 s-1; K2 = 2.8×103 M-1, kf2 = 3.4×104 M-1s-1, kb2 = 12.14 s-1. 
 
Hydroxo-bridges in Cu(II) complexes are not rare. There are many µ-hydroxo-Cu(II) 
examples [24-28] with one or two hydroxo-links. Geometry around the two Cu(II) centers are 
not always the same in each complexes, but typically Cu-Cu distance is 2.8 – 3.1 À and bond 
angle at the OH is 95° – 105° [24-28]. Molecular calculation program CAChe helped to 
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 demonstrate possible structures of Cu(II)2-TRH2 dimer. The linkage Cu-OH-Cu is bent due to the 
sp3 hybridization of the oxygen. Other parts of the peptide molecules may interact at convenient 
distances. Figure 4-9 shows one possibility, in which the lactam oxygen of one pGlu residue 
occupies an axial position of the other Cu(II) center. The bond geometries are in rather good 
agreement with literature: Cu-Cu distance: 3.06 Å, and Cu1-OH--Cu2 angle: 95.1°. Water 
molecule may also act as a bridge bond [29,30]. Molecular calculation also suggested four 
member ring formed by Cu-OH-Cu-H2O, in which the water is an apical ligand brought 
relatively closer to the metal center. 
 
 
Figure 4-10. Simulated and experimental currents of CE process vs ω1/2. 
Currents at 0.10 mM and 1.78 mM are plotted against ω1/2. Following Eq. (4-3) – Eq. (4-5):  
K1 = 1×105 M, kf1 = 500 M-1s-1, kb1 = 0.005 s-1; K2 = 2.8×103 M-1, kf2 = 3.4×104 M-1s-1, kb2 = 12.14 s-1. 
 
In all suggested structures, the previous “equatorial” ligands are off plain. The square 
planar configuration of Cu(II) is distorted. This distortion is not favored by a d8 form of Cu(III), 
meaning the redox potential of the distorted form shall increase. The binuclear complex is likely 
to be electroinactive in the applied potential range, which fits our hypothesis. 
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Figure 4-11. CAChe calculation of a possible structure of dimer Cu(II)2-TRH2. 
An OH- acts as a bridge. The lactam oxygen of the pGlu residue from the right monomer coordinates with Cu(II) of 
the left monomer in the apical position. 
 
The hypothesis that dimer formation is responsible for the behavior of Cu(II)-TRH and 
the analogous MeHisTRH complex, but that there is no analogous behavior of TRHOH is 
consistent with the observations as well. We interpret the difference in the behavior of the latter 
(compared to the former two) complex based on electrostatics. In the case of TRHOH, There is 
an added electrostatic barrier to dimer formation, inhibiting it. 
Since the simulated currents match the experimental values rather well in the applicable 
concentration or rotation frequency range, it shall be deduced that the values I CE / i E only 
decreases at certain rotation frequency as concentration decreases. The simulation has verified 
that a dimer complex of Cu(II)2-TRH2 very possibly exists. Its carries a negative charge at the 
hydroxo-bridge that links the two Cu(II) centers. 
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 4.5. Conclusions 
Major Cu(II) complex of TRH formed in a still solution is not electroactive. Electric field 
perturbs equilirbia and gives rise to current. RRDE proves useful in the kinetics study. We have 
found that multiple chemical processes accompany the redox reaction of the Cu(II) complexes of 
TRH. A binuclear Cu(II)2-TRH2 cluster is suggested. Molecular simulation suggests distortion of 
the Cu(II) coordination toward square pyramidal structure, which is less favored by d8 of Cu(III) 
oxidation state. The dimer is then less electroactive. 
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5. The Electrochemistry of Cu(II) Complex of the Octarepeat Peptide of the Prion Protein 
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 5.1. Abstract 
 
The octarepeat peptide of prion protein interacts with Cu(II) under physiological 
conditions. We have found it also binds Cu(I). The tryptophan side chain may participate. Cyclic 
voltammetry shows diffusion-controlled stripping-free curves of Cu(II) reduction with presence 
of Ac-PHGGGWGQ-NH2, a single unit of the octarepeat region. Visible spectroscopy serves to 
identify any Cu(II) complex of Ac-PHGGGWGQ-NH2 based on its absorption around 630 nm. 
Increasing the peptide concentration shifts the overall wave of Cu(II)/Cu(I) reduction to more 
positive potentials. The Cu(I) and Ac-PHGGGWGQ-NH2 coordination does not display a single 
stoichiometry in the phosphate-tartrate buffer used. Multiple components and exchange 
processes exist.  
This work is supportive of the neuro-protective function of the prion protein. 
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 5.2. Introduction 
Prion protein is believed to be responsible for a group of neurodegenerative diseases in its 
aggregated form [1-3]. Metal ions are found to interact with prion protein. A few binding sites 
have been identified, mainly around His residues [4-7]. The most interesting fragment is the N-
terminal octarepeats, residues 59-91 containing tandem copies of (Ac-PHGGGWGQ-NH2). It is 
a highly conserved domain in different species [8], implying roles in the normal functions of the 
protein. It is generally agreed by most results that each octarepeats binds one Cu(II) ion at 
physiological pH [9-11] and the HGGGW sequence is the fundamental binding unit [11]. Other 
stoichiometries at low Cu(II): peptide ratios have been noted [12]. A crystal structure of Cu(II)-
HGGGW [13] indicates equatorial binding at one His nitrogen, two deprotonated peptide amide 
nitrogens, and the carbonyl oxygen of the second Gly. 
Suggested functions of the prion protein include regulation of metal toxicities, especially 
those of Cu(II)[14-17]. Excess Cu(II) in mammal body is reduced by superoxide or reducing 
agents such as ascorbic acid and GSH to generate Cu(I). This unstable product may react with 
hydrogen peroxide to produce very reactive hydroxyl radicals via Habor-Weiss reaction [18, 19]: 
Cu(I) + H2O2 → Cu(II) + OH- + OH?     Eq. (5-1) 
The produced OH? is known to be damaging [20]. Shiraishi et al. have found that the octarepeat 
fragment binds copper resulting in suppressed copper-induced generation of reactive oxygen 
species [21]. A few research groups claimed that octarepeats peptide reduced cupric ion to 
cuprous ion, and the presence of Trp residue was critical [22-24]. Most recently, Chacon et al. 
showed reduced neuron density in rat brain tissues upon Cu(II) administration, and this toxicity 
was suppressed by Ac-PHGGGWGQ-NH2 [17]. Moreover, replacement of the Trp but not the 
metal binding His residue by Ala decreased the protecting effect of the peptide. 
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 Notably, though numerous studies have been carried out on the interaction of metal ions 
and the prion protein and its various fragments and redox activity is discussed, electrochemical 
studies are rather rare. Bonomo et al. [25] observed an irreversible reduction from Cu(II)-Ac-
PHGGGWGQ-NH2. The authors assigned this signal as coordinated Cu(II) being reduced to 
Cu(I) species, which partially dissociated from the peptide ligand. Little effort has been made by 
means of electrochemistry aside from that. 
A great number of proteins interact with copper in both bivalent and monovalent states. 
Electrochemical methods allow insights of metal-ligand interactions and should not be excluded 
from the studies of prion protein and Cu(II) interactions. Cu(II) ion undergoes 2-step reduction to 
produce elemental copper. Because of the fast disproportion of Cu(I) ion, in aqueous solutions 
reduction of Cu(II) appears to be a 1-step 2-electron transfer. The reactions can be written as: 
Cu(II) + e = Cu(I)        Eq. (5-2) 
E0 = 0.153 V vs. NHE [22], - 0.056 V vs. Ag/AgCl 
2Cu(I) = Cu(II) + Cu(0)       Eq. (5-3) 
Ligand existence may shift the potentials to reduce Cu(II) and Cu(I), such as acetonitrile 
[23]. Particularly on ligand-affected Cu(II) electrochemical reactions: 
Cu(II)Lp + e = Cu(I)Lq + (p-q)L      Eq. (5-4) 
Cu(I)Lq + e = Cu(0) + qL       Eq. (5-5) 
the redox potentials and complex stability constants follow the equation [24]: 
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 This chapter describes simple cyclic voltammetry technique on a microelectrode that 
gives us information otherwise unseen. Some comments on the neuro-toxicity and protective 
effects associated with Cu(II) and Ac-PHGGGWGQ-NH2 will also be addressed. 
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 5.3. Experimental 
 
5.3.1. Chemicals 
The prion protein octarepeat fragment (Ac-PHGGGWGQ-NH2) and its five-residue 
fragment Ac-PHGGG-NH2 were synthesized by the Peptide Synthesis Service at the University 
of Pittsburgh. HPLC data showed that each peptide had a purity of 99%.  
Artificial cerebral-spinal fluid (aCSF) contained 145.0 mM NaCl (EMD Chemicals, 
Gibbstown, New Jersey), 1.2 mM CaCl2 (EMD Chemicals), 2.7 mM KCl (EMD Chemicals), 1.0 
mM MgCl2 (Fisher Sci., Fairlawn, New Jersey), and 2.0 mM NaH2PO4 (J.T.Baker, Phillipsburg, 
New Jersey). Phosphate buffer contained 10.0 mM sodium phosphate monobasic (J. T. Baker), 
3.0 mM sodium potassium tartrate (J. T. Baker, re-crystallized twice from water), and 0.10 M 
potassium nitrate (Acros, Morris Plaines, New Jersey). Non-buffered solution contained 0.10 M 
potassium nitrate (Acros). A NaOH (J. T. Baker) solution of no lower than 4 M concentration 
was used to bring the pH up to 7.43 - 7.46. A NaOH solution of 0.05 M was added to 
spectroscopic cuvette for observation of Cu(II)-Ac-PHGGGWGQ-NH2 forming. Copper sulfate 
pentahydrate (J.T. Baker) was re-crystallized from water. All other reagents were used without 
further purification, but purities were taken into account in preparation. 
All solutions were prepared using water from an A10 synthesis water system (Millipore, 
Billerica, Massachusetts, USA). All pH values were measured with an Accumet® pH meter 
(Fisher Sci.), calibrated before each use. Calibration of the pH meter typically was carried out at 
36 - 37 °C. 
5.3.2. Instruments: 
The electrochemical cell was a two-layer glass cup with a home-made Styrofoam lid with 
holes. Three-electrode system consisted of a BAS Ag/AgCl reference electrode (Bioanalytical 
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 Systems, West Lafayette, Indiana), a Platinum grid auxiliary electrode (Goodfellow, Devon, 
Pennsylvania), and a micro-disk working electrode made with 30 µm carbon fiber (World 
Precision Instruments, Inc., Sarasota, Florida). Unless stated, potentials reported in this chapter 
are against Ag/AgCl. The exposed electrode area of the micro-disk was calibrated with 0.301 
mM ferricyanide reduction wave at room temperature. The solution was in 0.10 M KNO3 and 
0.15 M KCl. Calculated A = 8.55 × 10-6 cm2. (Limiting current at 0.00 V = 1.36 nA. D = 7.09 × 
10-6 cm2/s in 0.10 M KNO3 [26]).  
Potentials were scanned by an Epsilon EC potentiostat (Bioanalytical Systems, Inc.). A 
Colora WK-5 Kryo-thermostat (Colora, Germany) provided water bath to the cell which 
maintained the solution at 36.7 – 37.2 degree Celsius measured in the cell. All electrochemical 
experiments were conducted at this temperature range. Between each two runs, working 
electrode was polished with 0.05 µm alumina (Buehler Ltd, Lake Bluff, Illinois, USA) slurry in 
water. Each solution (3.0 ml or less) was de-oxygenized with 4.8 grade argon (Valley National 
Gases, West Mifflin, Pennsylvania) for at least 10 minutes. The argon flow was then kept above 
the solution at lower rate during the whole course of experiments. Obtained voltammograms 
were processed with PeakFit (Jandel Sci Software, San Rafael, California) to get first derivative 
(to find half wave potentials) using Savitzki-Golay 1st derivative function at 4.0% - 8.0% level.  
In the thermodynamic measurements (half wave potentials at varied peptide 
concentrations), Ag/AgCl reference electrode was checked against saturated calomel electrode 
(SCE) (Bioanalytical Systems, Inc) daily with the same phosphate-tartrate buffer used in the 
cyclic voltammetry experiments. The potential of employed Ag/AgCl electrode were -12 to -14 
mV against SCE in all measurements.  
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 Visible spectra were taken with a HP 8453 spectrometer (Hewlett and Packard, USA) 
using a 1 cm quartz cuvette (Starna Cells, Inc., Atascadero, California). The buffer was used as 
blank. Spectra were all taken at 5 second integration and reported either as original or sampled 
every 5 points. 
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 5.4. Results 
Diffusion coefficient of a redox active species is important in analyzing its 
voltammograms. The value of aqueous Cu(II) ion at 37 °C can be calculated from the constant 
Dη/T = 2.23 ± 0.37 × 10-10 cm2poise/sK [27]. Using dynamic viscosity values of water at 35 and 
40 °C (797.7 and 653.2 ×10-5 poise) the kinematic diffusion coefficients were calculated to be 
8.47×10-6 and 10.7 ×10-6 cm2/s. By assuming linear increasing of D with temperature between 35 
and 40 °C,  calculated D value at 37 °C is 10.0 ± 1.6 × 10-6 cm2/s. 
5.4.1. Oxidation of Ac-PHGGGWGQ-NH2 
On a 1 mm diameter glassy carbon electrode, the peptide in pH 7.4 aCSF gives an 
irreversible oxidation peak at 0.80 V (Figure 5-1). This potential is within the reported potential 
range of Trp and the peak shape also agrees with available literature [26].  
 
 
Figure 5-1. Cyclic voltammograms of Cu(II) and Ac-PHGGGWGQ-NH2 in aCSF  
on 1 mm glassy carbon electrode. 
All concentrations were 0.50 mM. Scan rates were 200 mV/s. 
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 5.4.2. Oxidation of Cu(II) ion and Ac-PHGGGWGQ-NH2 mixture 
At a 1 mm diameter glassy carbon electrode, an equimolar solution of Cu(II) and Ac-
PHGGGWGQ-NH2 in pH 7.4 aCSF displays an irreversible oxidation with a peak potential of 
0.82 V (Figure 5-1). The peak current corresponds to more than a 1 electron transfer, considering 
that the diffusion coefficient of Cu(II)-Ac-PHGGGWGQ-NH2 is on the order of 10-6 cm2/s. After 
subtraction of the peptide voltammogram from the mixture voltammogram, a “net” oxidation 
peak is obtained at 0.825 V. This should be ascribed to the oxidation of the complex [29, 30]. 
The peak current is still higher than 1 electron transfer.  No reversed signals have been observed. 
Similar phenomena have been reported with peptide ligands bearing Tyr residue, another 
electroactive residue [31]. According to the authors, the oxidation of Cu(II) to Cu(III) and of the 
Tyr residue are additive. The peptide oxidizes at a potential less positive than the Cu(II)-peptide 
complex. Its oxidation products rapidly reduce Cu(III)-peptide. These homogeneous reactions 
consume Cu(III) complex, resulting in the absence of a cathodic signal in the voltammetry of the 
complex. The Oxidation potential of Trp is less positive than the Cu(II) complex. A similar 
interpretation may be imposed on the Cu(II)-Ac-PHGGGWGQ-NH2 complex. Products of 
oxidized Ac-PHGGGWGQ-NH2 rapidly react with Cu(III) species thus no cathodic wave is seen 
on the reverse sweep.    
5.4.3. Cu(II)-Ac-PHGGGWGQ-NH2 binding 
The coordination of Cu(II) and Ac-PHGGGWGQ-NH2 can be verified by the color of the 
complex. Cu(II)-peptide complexes often display characteristic bands in blue to violet region. 
Bonomo et al. reported maximum absorption (λmax) at 614 nm of the complex at pH 6-8 [25]. 
Luczkowski et al. reported 621 nm for the species CuH-2L (L = Ac-PHGGGWGQ-NH2) with 
logβ = -8.87 ± 2 [32], which accounted for 90% of total Cu(II) species at pH 7.4. The λmax is 
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 high for a set of equatorial ligands: imidazole, 2 amide, carbonyl (NNNO), but low for an NNOO 
environment [33, 34].  The crystal structure [35] shows that there is an axial water hydrogen-
bonded to the Trp side chain. The axial bond distorts the square planar structure of Cu(II) toward 
a square pyramid structure. According to Billo [34], such axial bonding in a Cu(II) complex 
destabilize the complex and red-shifts the λmax.  
 
 
Figure 5-2. Visible spectra of Cu(II)- Ac-PHGGGWGQ-NH2 mixture titrated with NaOH.  
Starting volume is 960 µl. Each additional curve indicates one aliquot of 2 µl 0.050 M NaOH added.  
Only pH of last solution has been measured and annotated. At beginning,  
[Cu(II)] = [Ac-PHGGGWGQ-NH2] = 0.30 mM.  
Solution also contained 0.10 M KNO3.  
 
The imidazole moiety of His residue is basic. Its pKa is 6.0 when forming CuH-2L 
complex [32]. Cu(II) starts to interact with Ac-PHGGGWGQ-NH2 when pH is above 5.3 or so 
[11], when the His imidazole starts getting deprotonated. In non-buffered solutions the imidazole 
moiety remains protonated, unless external OH- is added. Figure 5-2 shows in non-buffered 
solution, gradually added OH- shift the Cu(II) absorption band from aqueous free ion to Ac-
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 PHGGGWGQ-NH2 bounded state. The further blue shift beyond 600 nm at pH 8.3 is possibly a 
CuH-3L species [32].  
5.4.4. Reduction of Cu(II) in presence of Ac-PHGGGWGQ-NH2  
Ac-PHGGGWGQ-NH2 binds Cu(II) under certain circumstances. Interaction of Ac-
PHGGGWGQ-NH2 with Cu(I) has not been looked into to date.  
Reduction of aqueous Cu(II) leads to solid Cu deposition [36]. On a microelectrode, the 
presence of Cu° is deduced from the presence of a stripping peak. If the reduction of Cu(II) does 
not yield a stripping peak, we infer that the product is a soluble Cu(I) species. 
 
 
Figure 5-3. Cyclic voltammograms of Cu(II) reduction in presence of Ac-PHGGGWGQ-NH2  
in un-buffered solution. 
 Cu(II) and Ac-PHGGGWGQ-NH2 are 0.30 mM each in 0.10 M KNO3. Darker and lighter lines indicate different 
scanning range. 
 
Shown in Figure 5-3, Cu(II) is reduced at a microelectrode in presence of equimolar Ac-
PHGGGWGQ-NH2 in unbuffered KNO3 solution. In this solution there is no Cu(II) complex of 
Ac-PHGGGWGQ-NH2 formed, as indicated in Figure 5-2. The CV scanned from 0.4 V to -0.15 
V gives a diffusion-controlled wave at 0.096 V. No oxidation wave is observed indicating no 
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 deposition occurs during reduction process. The potential is much more positive than that of 
Cu(II) ion, -0.056 V vs. Ag/AgCl. The limiting current corresponds to 1-electron transfer with 
diffusion coefficient 1x10-5 cm2/s. This value is in good agreement with that of aqueous Cu(II) 
ion at 37 °C [27]. A second reduction wave occurs at -235 mV. This wave features a slightly 
lower steady state current than the first one. This wave is accompanied by an anodic stripping 
peak. 
The simplest explanation for the data is that Cu(II) is reduced to a Cu(I)-peptide complex 
at the first wave.  This complex is reduced to Cu(0) at the second wave 
Cu(I) ion is a soft Lewis acid. It binds “soft” ligands better. Among its most well known 
ligands are the phenanthroline family to which the Cu(I) indicator bathocuproine belongs [22-24]. 
A mixed-ligand complex of Cu(I) with a member of this family and triglycine existed transiently 
when reduced by cyclic voltammetry, which called for at least two soft nitrogen donors to form a 
relatively stable Cu(I) complex [37]. In the case of Ac-PHGGGWGQ-NH2, the Trp may play a 
role as a potential nitrogen donor. Figure 5-4 shows the voltammograms of the Cu(II)-Ac-
PHGGG-NH2 system. The stripping-free curve (bold) shows that Ac-PHGGG-NH2 also prevents 
Cu(I) disproportion, possibly by binding Cu(I), too. The first half-wave potential is 0.041 V, less 
positive compared to that of the Ac-PHGGGWGQ-NH2 (0.096 V). The second half wave 
potential is -0.141 V, more positive compared to that of Ac-PHGGGWGQ-NH2 (-0.235 V). The 
separation of the two reduction steps is less than in the case of the octa-peptide. These 
observations are consistent with a weaker interaction of Cu(I) with Ac-PHGGG-NH2 than with 
Ac-PHGGGWGQ-NH2. The Trp residue is most likely responsible. In other words, the Trp side 
chain, or more exactly the indole nitrogen, may be capable of interacting with Cu(I).. 
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Figure 5-4. Cyclic voltammograms of Cu(II) in presence of pentapeptide Ac-PHGGG-NH2  
in un-buffered solution.  
Cu(II) and Ac-PHGGG-NH2 are 0.30 mM each. Solutions contain 0.10 M KNO3. 
 
The reduction half-wave potential is useful to evaluate the binding of Ac-PHGGGWGQ-
NH2 with Cu(II) and Cu(I). Regression of E1/2 against ligand concentration at equilibrium 
provides information of formation constants ratio of the two oxidation states in its intercept, and 
information of difference in ligand numbers in the two complexes in its slope (see Eq. (5-6)). 
The Cu(II)- Ac-PHGGGWGQ-NH2 system is then put in phosphate buffer with large excess of 
tartrate with respect to copper species. In this fashion Cu(II) ion will not precipitate because of 
coordination with tartrate. It also mimics the physiological condition in which Cu(II) is bound 
and virtually no free aqueous Cu(II) ion exists.  
Figure 5-5 shows the voltammograms of Cu(II) in the presence of varying concentrations 
of peptide. The backward scan has been checked for Cu(II) to peptide ratio 3:4 and 3:30 to make 
sure no deposition forms within certain potential range (data not shown). At least two waves are 
seen in each voltammogram. Taking the first derivative of each voltammogram reveals another 
wave in between the two clearly seen ones. The current of this wave is low. It indicates a low 
abundance copper species. Figure 5-6 shows how half-wave potentials of the three waves vary 
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 with Ac-PHGGGWGQ-NH2 concentration. The first reduction wave features wider differential 
peaks than a reversible 1-electron redox process. They are typically asymmetrical and composed 
of multiple components. An “overall” E1/2 is found for each voltammogram, which is the lowest 
point of the differential peak (Differential peaks are downward). The overall E1/2 shifts toward 
positive potentials with increasing Ac-PHGGGWGQ-NH2 concentration, meaning that Cu(I) is 
ligated to more peptide ligands than Cu(II). The second wave is not affected by Ac-
PHGGGWGQ-NH2 concentration, meaning the oxidized and reduced forms contain same 
number of Ac-PHGGGWGQ-NH2 ligands. The third wave shifts toward negative potentials. Its 
differential peak is sharp with a relaxation resembling an exponential decay. This shape is a sign 
of insoluble redox product formation. Consistently it indicates Ac-PHGGGWGQ-NH2 as a Cu(I) 
ligand stabilizes Cu(I) from being reduced to Cu(0). 
 
 
Figure 5-5. Cu(II) reduction in presence of varied Ac-PHGGGWGQ-NH2 concentrations. 
Cu(II) is 0.30 mM in 10.0 mM phosphate buffer (pH 7.43) with 3.0 mM tartrate.  
Buffer blank is subtracted from each voltammogram. 
113 
  
Figure 5-6. Half-wave potential shift of Cu(II) reduction  
with varied Ac-PHGGGWGQ-NH2 concentration. 
Cu(II) is 0.30 mM in each solution. All in 10.0 mM pH 7.43 phosphate buffer with 3.0 mM KNaTar.  
♦: first wave, ?: second wave, ?: third wave. 
 
To analyze these potential data we need to know the coordination profile of Cu(II) in the 
system. Visible spectra of same composed solutions show blue-shifting of maximum absorption 
bands (λmax) as peptide concentration increases (Figure 5-7). With presence of large excess 
tartrate, Ac-PHGGGWGQ-NH2 at this pH is not competitive enough compared to tartrate. The 
equilibrium 
Cu2+ + Ac-PHGGGWGQ-NH2 → Cu2+- Ac-PHGGGWGQ-NH2  
becomes 
Cu2+-Tar + Ac-PHGGGWGQ-NH2 → Cu2+-Ac-PHGGGWGQ-NH2 + Tar  
The Cu(II)-Tar complexation system is a complicated multi-components system 
involving multi-nuclear species [35]. The above equations do not show actual stoichiometry 
related to these complexes.  
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Figure 5-7. Visible spectra of 0.30 mM Cu(II) in presence of varied concentrations of Ac-PHGGGWGQ-NH2. 
Solution contains 10.o mM phosphate buffer (pH 7.4) and 3.0 mM tartrate.  
Legends indicate molar ratio of Cu(II) to Ac-PHGGGWGQ-NH2. 
 
By subtracting the Cu(II)-tar spectrum from each with Ac-PHGGGWGQ-NH2, we get 
spectra representing A/b = [Cu(II)-Ac-PHGGGWGQ-NH2]⋅ ( )2NHPHGGGWGQAcCu −−−ε , where b is 
the path length. The “net” spectra all have λmax at 630 nm, which should represent the Cu(II)- 
Ac-PHGGGWGQ-NH2 complex. Calculated using εCu-PHGGGWGQ, 621nm from reference [32] and 
εCu-Tar, 630nm from our experimental data, the Cu(II)- Ac-PHGGGWGQ-NH2 formed at pH 7.4 
with tartrate present is no more than 15% of total Cu(II) when Ac-PHGGGWGQ-NH2 is 1.50 
mM, 5 times the total Cu(II). For all the Ac-PHGGGWGQ-NH2 concentrations investigated, the 
Cu(II)-Ac-PHGGGWGQ-NH2 complex formed only accounts for at most a few percent of total 
peptide  
The data in Fig 5 consistently indicate that the first wave in the Cu(II)-Ac-PHGGGWGQ-
NH2 system is the reduction of Cu(II)-Tar to Cu(I)-Ac-PHGGGWGQ-NH2. The second wave we 
believe is the reduction of Cu(II)-Ac-PHGGGWGQ-NH2 to Cu(I)-Ac-PHGGGWGQ-NH2, based 
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 on its low current. The third wave corresponds to reduction of Cu(I) complexes of Ac-
PHGGGWGQ-NH2 to Cu(0). 
For the reduction  
−−− +=++ 2)(2 )()( nTarLImCumpLmeTarIICu pnmnm ,    Eq. (5-8) 
half wave potential is expressed as 
]ln[]ln[ L
F
RTpEL
mF
RTEE Tar
mp
TarL +=+=     Eq. (5-9) 
In Eq. (5-9), EL stands for the half wave potential of the Cu(II) reduction in presence of L 
(i.e., Ac-PHGGGWGQ-NH2), ETar stands for the half wave potential of Cu(II) reduction with 
presence of tartrate only, and p stands for number of peptide ligands per Cu(I) (generally, it is the 
difference in numbers of ligand L per metal at the reduced and oxidized forms.. We will be able 
to used [L]total instead of [L]eq. The slope of the regression of EL against log[L]total is the value of 
RT/F (0.0615 V at 37 °C) multiplied by p. By regression of E1/2 of a wave vs. log[L], the value p 
can be obtained.. 
Though the E1/2 of the first wave displays some linearity against log[L]total, the broad 
differential peaks of the waves prevent us from using the E1/2 values to determine the actual p 
value. The wave is associated with various ligand exchange processes. Any quantitative 
regression is meaningless. Nevertheless, it is still a firm indication that Ac-PHGGGWGQ-NH2 
as a Cu(I) ligand stabilizes Cu(I) from disproportion or precipitation. The number of Ac-
PHGGGWGQ-NH2 ligand per Cu(I) could be 1 and up, which is not resolved under current 
conditions. Consistently, the E1/2 of the third wave is neither linear against logrism of ligand 
concentration, representing the reduction of multiple forms of Cu(I)-Ac-PHGGGWGQ-NH2 to 
Cu(0) metal. 
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 5.5. Discussion 
We have demonstrated that the Cu-prion octarepeat has a rich electrochemistry.  As 
others have observed, Cu(II) forms a complex with Ac-PHGGGWGQ-NH2 at pH 7.4 in buffered 
aCSF.  This complex is oxidizable at a potential near 0.8 V vs Ag/AgCl (3M NaCl).  The natural 
peptide’s tryptophan residue is oxidized at a similar potential.   
The reduction of Cu(II) in the presence of Ac-PHGGGWGQ-NH2 is more complicated.  
Our data are not consistent with the idea that the peptide reduces Cu(II) to Cu(I). If it did so, we 
would not see the spectrum in the 6 – 700 nm range, and we would not see a wave for the 
reduction of Cu(II) to Cu(I). If the product were a stable complex of a peptide or oxidized 
peptide and Cu(I), then the only reduction wave would be to Cu(0). We see reduction waves 
corresponding to products other than Cu(0) (i.e., freely diffusing products) . 
In unbuffered solutions, Ac-PHGGGWGQ-NH2 stabilizes Cu(I).  The pentapeptide Ac-
PHGGG-NH2 stabilizes Cu(I) as well, but not as much as the octapeptide.  Thus, the tryptophan 
stabilizes Cu(I) to a degree. In phosphate-buffered tartrate at pH 7.43 there are three reduction 
waves, one of which is the reduction of Cu(I) to Cu(0).  The presence of tartrate avoids 
precipitation of copper ions as oxides/hydroxides but adds a competitive ligand.  On the other 
hand, the presence of tartrate is at least qualitatively similar to the situation in vivo where Cu is 
protein-bound. The first two waves apparently correspond to tartrate-bound Cu(II) and peptide-
bound Cu(II). Under the conditions of this experiment (excess peptide), multiple forms of 
complex are formed upon reduction of Cu(II) to Cu(I). The third wave has the characteristic 
shape of a reduction to metal, and corresponds to Cu(I) to Cu(0). 
Using bathocuproine as a Cu(I) indicator to monitor Cu(I) level could cause 
methodological artifact [39], as its much stronger binding to Cu(I) than to Cu(II) increases the 
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 oxidizing power of Cu(II) [40]. Under physiological conditions, there are reducing reagents such 
as ascorbic acid and GSH. Though the presence of Ac-PHGGGWGQ-NH2 brings the potential to 
reduce Cu(II) to Cu(I) to more positive values, it is still not conclusive to assign a copper-
reducing capability to the peptide. The peptide Ac-PHGGGWGQ-NH2 is capable of stabilizing 
Cu(I) reduced by other reducing reagents. This means the Cu(I) can become less reactive with 
presence of the peptide. In other words, the oxidation of Cu(I) state to Cu(II) state, as in Habor-
Weiss reaction, is unfavorably affected. Very possibly, the full length prion protein possesses 
similar ability, which supports the anti-oxidative stress function of the protein. 
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 5.6. Conclusions 
The peptide Ac-PHGGGWGQ-NH2 mimics a Cu(II) binding unit in the prion protein 
octarepeat region. The electrochemical property of Ac-PHGGGWGQ-NH2 does not enable it to 
reduce Cu(II). However, its coordinating property with Cu(I) may facilitate the reduction. Ac-
PHGGGWGQ-NH2 interacts with both Cu(II) and Cu(I). It binds electrically generated Cu(I) to 
prevent it from disproportion. The tryptophan side chain may be involved in the binding. Our 
work supports the of anti-copper toxicity function of the prion protein.  
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